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Flexible lipid vesicles have the potential of complementing or even replacing traditional 
needle injection methods for insulin delivery. Vesicles are made flexible by the incorporation of 
a chemical surfactant which may also hinder their stability. We studied the changes in the size 
and apparent flexibility of vesicles with varying surfactant concentrations over time and the 
effects these changes have on vesicle diffusion. We found that increased surfactant 
concentrations lead to greater size fluctuations. In addition, we witnessed a significant decrease 
in the flexibility of vesicles over six weeks, while the diffusivity of surfactant infused liposomes 
increased over a single week. Our data suggests that while surfactants are necessary in vesicles 
for transdermal drug delivery, their long-term stability is uncertain. Using our diffusion data, we 
developed a model to estimate the insulin delivering capacity of a hypothetical insulin patch 
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1.1 What is Diabetes, and Why is it Important? 
According to the American Diabetes Association (ADA), diabetes is a disease in which 
the body does not produce or properly utilize insulin (“All About Diabetes”, 2009). Insulin is a 
hormone necessary for cells to intake glucose, which in turn provides energy for proper cellular 
function. An untreated diabetic can suffer from conditions ranging from heart disease, stroke, 
high blood pressure, renal failure, nervous system disease, as well as a gamut of other 
complications. Synthetic insulin, amongst other treatments, can be used to help diabetics control 
their blood glucose homeostasis. 
Diabetes is the sixth leading cause of death in the United States and affects an estimated 
20.8 million people (7% of the population), with an additional 40.1 million Americans who have 
been identified as at-risk for developing the disease. In the year 2000, approximately 170 million 
people worldwide were affected with diabetes, and this number is expected to double by the year 
2030 (Hadjiyanni & Drucker, 2007). In 2003, IMS Health reported that insulin sales alone 
reached $2.2 billion dollars, with the total diabetes therapy product sales reaching $7.8 billion. 
However, this is a small amount compared to the $132 billion (2002 statistic) in medical 
expenditures for treating diabetes-related conditions and ailments reported by the ADA. Such a 
large gap in spending for medications versus treatment of diabetes-related complications 
demonstrates the potential for enhanced diabetic therapy.  
Both the widespread impact of diabetes and the complexity of care for diabetics warrant 
greater attention paid to the development of more effective diabetes treatments and the 




1.2 Why Was Team No More Needles Formed? 
Team No More Needles was conceived under the blessings of the Gemstone 
Undergraduate Research Program at the University of Maryland, College Park. Consisting of 
cross-disciplinary scholars with interests in the synthesis of research, technology, and ethics, the 
Gemstone Honors program aligned a group of students united by the goal of removing needle 
usage from diabetes care. Team No More Needles has spent the last four years tackling the 
varied facets of this challenge, exploring angles from dense technical perspectives to the many 
slants of business opportunities. 
While the expansive pharmaceutical sector has generally been successful in developing 
various new drugs and delivery devices, it was surprising that no clear alternative existed on the 
market for diabetics who require daily doses of insulin. After careful debate, the team decided 
that liposomes, microscopic molecules capable of encapsulating drugs, were the most 
appropriate candidates for research as a transdermal insulin delivery method. 
As laboratory research progressed, the team decided to pursue the business potential of an 
insulin delivery device by designing a transdermal insulin patch that used liposomes as the 
delivery medium.  As a result, the team wrote a business plan to advertise both the societal 
advantages and potential business opportunities of bringing an insulin patch to market (See 
Appendix A).   In the spring of 2008, Team No More Needles entered three business plan 
competitions with this potential product, under the name SymViva Technologies. They placed 
third in the Greater Baltimore Technological Council’s Mosh Pit Business Plan Competition, 
second in the undergraduate category for the University of Maryland 50k Business Plan 
Competition, and were semi-finalists in the Mid-Atlantic Business Plan Competition, earning a 




1.3 The Problem with Needles 
Although needles have served as the traditional method of delivering insulin, this 
technique continues to present several problems, mainly due to its invasive nature. Needle-based 
delivery is not only tedious and painful, but also a potential biohazard. Patients who reuse 
needles and syringes risk the transmission of diseases as well as an increased chance of infection. 
Despite recommendations from manufacturers which state that needles should be discarded after 
a single use, some patients find it more convenient and cost-effective to reuse needles (Insulin 
Administration, 2000).  
Frequent use of hypodermic needles can also cause physical deformations. Fat 
hypertrophy, or the formation of fatty growths at injection sites, is an unsightly problem. It is 
sometimes accompanied by fat atrophy or indentations on the skin caused by loss of fat under the 
skin’s surface (BD, 2008). Also, scarring can occur if is the same injection site is used too often 
(BD, 2008). 
Needle injections can also cause psychological discomfort for their users, which include 
anxiety and phobias associated with needles.  The fear of needles can inhibit patients from 
following a strict regimen of self-injections and blood glucose tests (Mollema et al., 2001). In 
fact, multiple studies have correlated poor glycemic control in type 1 diabetes patients with high 
levels of anxiety and phobic symptoms (Berlin et al, 1997, Zambanini et al., 1999).  Patients with 
needle-phobia experience a lowered quality of life due to these conditions (Mollema et al., 
2001). 
1.4 Why is More Research Needed? 
While current alternatives on the market address certain issues associated with needle 




diabetic life. Currently, diabetics may choose between modified needles and insulin pumps. For a 
short period of time, Exubera, a system of inhalable insulin delivery, was also available, but has 
since been removed from the market due to lack of acceptance by doctors and patients.  
Modified needle-delivery techniques consist mostly of insulin pens and automatic 
injectors, which do not circumvent the invasive nature of traditional needle injections. In the case 
of automatic injectors, the needle is typically surgically implanted and hidden from view (FDA, 
2008). This is favorable for patients who are most uncomfortable with penetrating the skin on a 
regular basis (BD, 2008). However, automatic injectors still present many of the physical and 
psychological disadvantages associated with traditional needle syringes.  
The most popular alternative on the market is the insulin pump. This small device is 
carried outside the body and is connected to subcutaneous tissue via a narrow flexible catheter 
(FDA). The pump allows for close control of insulin levels without multiple injections. It is also 
programmable to administer insulin when needed and delivers insulin with greater precision than 
traditional needle injections (ADA, 2008). One major disadvantage of the system is that the 
device must be on body at all times. Insulin pumps are relatively bulky to wear and the implanted 
catheter has in some cases been reported to become dislodged from a patient’s body. This poses 
obvious dangers as users should not go without insulin for extended periods of time (ADA, 
2008). Insulin pumps can be a hindrance to exercise, athletic activity, and even sleeping. They 
are also expensive, with the cost of a pump at around four to five thousand dollars (ADA, 2008). 
In 2006 Pfizer introduced inhaled insulin and promised that their product, Exubera, 
would revolutionize insulin delivery. However, after approximately one year on the market, 
Exubera was withdrawn from the market with a 2.8 billion dollar loss by Pfizer (Weintrab, 




the device itself was described as “cumbersome” by diabetics who used it. Moreover, a treatment 
regimen based on Exubera was estimated to cost 30% more than a regimen based on injections 
(Weintrab, 2007). With the decline of Exubera, no true alternative to needles exists on the 
market.  
While this niche has yet to be filled, there are several promising candidate methods that 
are vying for the spot. Primary among these is that of lipid vesicles, known as liposomes. These 
vesicles are essentially bubbles of fats that have the capacity to encapsulate drugs and proteins 
such as insulin for transdermal delivery – an idea first proposed in the early 1980’s (Mezei & 
Gulasekharam, 1980). While the skin serves as a potent boundary between the external 
environment and the interior of the body, vesicles have been found to have the capacity to pass 
through the stratum corneum (the outermost layer and main barrier of the skin) and ultimately 
reach capillaries below (Bouwstra & Honeywell-Nguyen, 2002). However, these results are not 
yet conclusive as many researchers have recorded contrasting results. As such, liposomes 
treatments are still largely in the experimental phase and the ultimate question as to whether or 
not liposomes are effective at transdermal drug delivery has yet to be answered. 
1.5 What Does Team No More Needles Hope to Accomplish? 
The primary objective of this project is to assess the viability of liposomes as a potential 
transdermal insulin delivery system for Type I Diabetics. We define ‘viability’ as stability of 
size, flexibility, and diffusivity of the liposomes over time, since changes in any of these three 
factors would dramatically alter the effectiveness of the liposome in delivering insulin. Another 
aspect in our definition of “viability” is testing of determined parameters in mathematical 
models. In order for the drugs to be viable, they must be able to withstand the manufacturing 




Our research questions are the following: 
1. How do the size, stability, and flexibility of liposomes of different surfactant 
concentrations change over time? 
2. How does surfactant concentration affect diffusivity of liposomes through a skin-like 
barrier?  
3. How do rates of diffusivity of liposomes with different surfactant concentrations change 
over time? 
4. Upon fitting the collected data to a mathematical model, what is the estimated extent of 
insulin delivery through the skin? 
From preliminary data collected in the lab, a secondary objective emerged to produce a 
model liposome patch design, and evaluate the potential business opportunity for marketing such 
a design.    
1.6 Outline of Study 
A formulation for the vesicles was achieved through the mentorship of Dr. Oluwatosin 
Ogunsola. With the additional guidance of Dr. Srinivasa Raghavan and Dr. Nam Sun Wang, 
multiple liposome samples were generated and analyzed according to our objectives. Stability 
over time was measured using a dynamic light scattering (DLS) laser, and elasticity was 
measured using an extruder. The data collected was used to determine the ideal ratio of 
surfactant to add to the liposome in order to achieve superior stability and elasticity.  
To achieve our second research question, agar gel samples were prepared and liposomes 
loaded with DII fluorescent dye were applied. The penetration of the liposomes through this 




1.7 General Study Hypotheses 
1. Increasing surfactant concentration of the liposome will result in more size fluctuations 
over time.   
2. The flexibility of the liposome will decrease over time, regardless of surfactant 
concentration. 
3. The diffusivity of liposomes through a skin-like barrier will decrease over time.   
4. Combining these three hypotheses, we ultimately predict that the viability of liposomes 





2. Literature Review 
2.1 Anatomy of the Skin 
 Human skin is composed of three major layers, the cellular epidermis, the dermis, and the 
subcutaneous (Figure 1). The outer most layer of the cellular epidermis is the stratum corneum. It 
is composed of 15-20 layers of corneocytes, keratin-filled dead cells, which are surrounded by 
crystalline lipid lamellae. (Bouwstra and Honeywell-Nguyen, 2002 & El Maghraby, 2008). 
These lipid lamellae of the stratum corneum are composed of lipids different from those of the 
plasma membrane of living cells. The main lipids found in the stratum corneum are ceramids, 
cholesterol, and free fatty acids. The chain lengths of these lipids are much longer than the chains 
of the plasma membrane’s phospholipids (Bouwstra and Honeywell-Nguyen, 2002). The 
organization of the stratum corneum is often described as a wall with the corneocytes as bricks 
embedded in a lipid mortar. These structures are 10-15 um thick when dry and up to 40 um thick 














Figure 1: Layers of the Skin 
 
The 3 major layers of the skin. Taken from Cancer Council Victoria. Common Skin Cancers. 
Brochure. Melbourne: 2007. 
 
The next layer, the dermis, is three to five nm thick and is composed of collagen and 
elastin proteins. Blood and lymphatic vessels, nerve endings, hair follicles, and sweat glands are 
all found in the dermis. The hair follicles and sweat glands are embedded in the dermis, but they 
extend through the cellular epidermis all the way to the skin surface (El Maghraby, 2008). Since 
blood vessels do not reach the cellular epidermis, nutrients and waste products must diffuse 
across the dermal-epidermal layer to reach the cellular epidermis (El Maghraby, 2008).    
To penetrate the skin, there are two main routes that molecules take: the trans-
appendageal pathway and the transepidermal (or transdermal) pathway. The trans-appendageal 
route is penetration through the sweat glands and the sebaceous glands associated with hair 
follicles. The transdermal route entails penetration of a substance through intact stratum 
corneum, which includes either maneuvering around the keratinocytes and diffusing through the 




the lipid domains (intercellular domain) (Figure 2) (El Maghraby, 2008). In both pathways, the 
stratum corneum is considered the rate-limiting barrier as its intercellular lipid domains present a 
major barrier to any molecule trying to penetrate the skin.  










Trans-cellular Pathway  Intracellular Pathway  
 
Figure 2: Bricks and mortar arrangement of the keratinocytes and intercellular lipid domains. 
The two sub-pathways of the transepidermal routes can be seen, with either penetration of the 
keratinocytes in the intracellular pathway or diffusion through the lipid domains while 
maneuvering around the keratinocytes in the transcellular pathway (adapted from El Maghraby 
et al., 2008). 
2.1 Diabetes 
2.1.1 Pathology of the Disease 
 Diabetes is a disease characterized by abnormal glucose metabolism resulting from 
defects in either insulin secretion or insulin action (Nathan, 1993). There are two classifications 
of diabetes: type I and type II. Type II diabetes is non-insulin dependent diabetes and is the more 
common form of the two, comprising 80-95% of all diabetes etiologies (Voltarelli, 2007). Type 
II diabetes is caused by a resistance to insulin or an inability to produce sufficient amounts of 
insulin. (Zimmet, 2001).  In most cases, type II diabetes is treated with medication and exercise, 
but up to one third of patients may ultimately require synthetic insulin supplements (Campbell & 




Type I diabetes, also known as insulin-dependent diabetes, is a cell-mediated 
autoimmune disease that results in the destruction of insulin-producing pancreatic β cells 
(Silvera et al., 2006). The dwindling supply of insulin leaves the body unable to maintain glucose 
homeostasis, and the resulting hyperglycemia (high levels of glucose in the blood) can lead to 
progressive dehydration, reduction of blood, shock, and ultimately, coma. Severe and common 
complications of hyperglycemia include: retinopathy and the associated potential loss of vision, 
nephropathy and associated renal failure, and peripheral or autonomic neuropathy along with 
associated gastrointestinal, genitourinary, and cardiovascular symptoms (Report of the Expert 
Committee, 2002). In Western countries, type I diabetes is the leading cause of limb amputations 
and blindness (Hadjiyanni & Drucker, 2007).  
In the early stages of type I diabetes, the patient’s own T-lymphocytes infiltrate the β 
cells, and as the disease progresses the β cells begin to disappear (Babaya, 2005). Type I diabetes 
patients show a clear reduction in the total mass of these pancreatic cells compared with non-
affected individuals (Davidson, 2000). The rate of β cell destruction varies among individuals, 
with rapid destruction common among infants and children, and slow destruction common 
among adults (Zimmet, 1994). Eventually, however, all patients suffering from type I diabetes 
must receive exogenous forms of insulin in order to survive (Zimmet, 2001). Studies have 
estimated that by the time type I diabetes is diagnosed only 10-20% of the patient’s β cells are 
still functioning (Knip et al., 2006). 
 There is a genetic predisposition to type I diabetes (Bonen, 2002). Individuals with a 
first-degree relative suffering from type I diabetes are 15 times more likely to develop the 
disease than individuals whose immediate families are unaffected (Hakonarson et al., 2007). 




diabetes, but only three, HLA (human leukocyte antigen), VNTR (variable nucleotide tandem 
repeat), and LYP (lymphocyte tyrosine phosphatase) have been conclusively linked to type I 
diabetes predisposition (Babaya, 2005). Concannon et al. analyzed data from 1,435 families and 
found evidence for type I diabetes linkage to 10 other chromosome regions, suggesting that there 
are more genes linked to genetic predisposition for type I diabetes. Despite the understanding 
that type I diabetes clusters in families, its mode of inheritance remains unknown (Concannon, 
2005).  
 In addition to genetics, specific environmental factors have also been associated with 
development of type I diabetes. According to a study conducted by the Diabetes Epidemiology 
Research International Group, there are significant differences in the incidence of type I diabetes 
among populations in different geographical areas. The group found that among patients 15 years 
of age, the average incidence of type I diabetes in Hokkaido, Japan was 1.7 per 100,000 people, 
while in Finland the incidence was 29.5 per 100,000 people (1998). Additionally, studies 
conducted on the incidence of type I diabetes in monozygotic twins revealed that only 13 - 33% 
are pair-wise concordant for type I diabetes (Kaprio, 1992). These results indicate the presence 
of differential exposure to environmental factors, as well as changes in lifestyle and 
environment, rather than post-conceptional genetic discordance. Moreover, approximately one-
fifth of Caucasians carry the HLA diabetes susceptibility gene and only 5% of them develop 
overt type I diabetes (Knip et al., 2006). Knip et al. suggest that genetic susceptibility, a trigger, 
and exposure to an exogenous antigen are all required for progression to type I diabetes to occur; 
if any of these three factors are missing than the risk of developing type I diabetes is minimal. 
Potential exogenous environmental factors contributing to the development of type I diabetes 




trigger the production of insulin auto-antibodies, and the timing of their introduction to infants 
seems to be of importance (Knip et al., 2006; Virtanen, 2000). Viruses have also been implicated 
in the triggering of type I diabetes, and it has been hypothesized that they can act as self-antigens 
to accelerate the autoimmune process through molecular mimicry (Knip et al., 2006).  
2.1.2 Insulin Treatment 
2.1.2.1 Insulin 
Insulin is a peptide hormone that is produced in the pancreas and facilitates the uptake of 
glucose by liver, muscle, and fat cells. The β-cells of the pancreas secrete insulin directly into the 
hepatic portal blood in response to hyperglycemia and sympathetic and parasympathetic 
stimulation. In healthy individuals the levels of insulin vary dramatically throughout the day, 
decreasing during times of exercise or fasting, and increasing during mealtimes (LeRoith, 2004).  
Insulin can be isolated from pork pancreases or synthesized chemically through 
recombinant DNA technology so that it is identical to human insulin. Additionally, rapid-, 
intermediate-, and long-acting insulin analogs have been created by the modification of one or 
two amino acids of human insulin (Chen et al., 2003). 
2.1.2.2 Insulin Delivery 
 Subcutaneous injection serves as the primary mode of insulin delivery (Owens et al., 
2003). Insulin is injected into the subcutaneous tissue of the upper arm, thigh, buttocks, or 
abdomen, where it forms an insulin depot from which it can be absorbed into the blood (Chen et 
al., 2003; Insulin Administration, 2000). To be able to reach the blood stream, insulin molecules 
must dissociate from their natural hexameric form into monomers or dimers so that it is small 




receptors on target cells and performs its biological activity (Chen et al., 2003). However, the 
dissociation step results in a lag phase between the subcutaneous injection and the time of insulin 
action. Consequently, at meal times the absorption of insulin is too slow to mimic the body’s 
rapid release of insulin (Brange, 1988). Through a single amino-acid substitution in human 
insulin, Brange et al. created an insulin analog that remains monomeric and is absorbed 2 to 3 
times faster than unmodified insulin while retaining its biological activity (1988).   
The modification of human insulin to produce insulin analogs, as well as the synthesis of 
human insulin through recombinant DNA technology, has allowed for the development of rapid-, 
intermediate-, and long-acting insulin (Insulin Administration, 2000).  Rapid-acting insulin 
(“bolus” insulin) includes insulin lispro and insulin aspart, both of which differ from human 
insulin by one or two amino acids in positions 28 and 29. These modifications make it less likely 
that the insulin will self-aggregate into hexamers (Chen et al., 2003). Insulin lispro and insulin 
aspart have onset times of 5-15 minutes and can therefore be administered at mealtime, 
increasing the quality of life for patients with type I diabetes (Gerich, 2002). Studies by Home et 
al. have demonstrated that the absorption of insulin aspart is twice as fast as the absorption of 
human insulin and after injections of insulin aspart, plasma glucose levels fell twice as rapidly as 
they did after human insulin injections (1999).  Studies on insulin lispro have found similar 
results, with one study finding that within 100 minutes of subcutaneous injection 90% of insulin 
lispro was absorbed compared to 180 minutes for unmodified human insulin (Gerich, 2002).   
While it is important to control the surge in blood glucose immediately following a meal, 
type I diabetes patients must also be concerned with maintaining normal glucose levels 
throughout the entire day. Since rapid-acting insulin is only effective for up to five hours, two 




(DeWitt & Hirsch, 2003). Intermediate-acting insulin has an onset time of four to ten hours after 
injection and is effective for 10 -18 hours (DeWitt & Hirsch, 2003). Intermediate-acting insulin 
refers to neutral protamine Hagedorn (NPH) or Lente insulin. NPH is regular insulin with the 
addition of protamine and lente insulin is regular insulin that has been bound to zinc. These 
additions make the insulin absorbed more slowly and thus are used as twice-daily basal insulin 
injections. Long-acting insulin, called ultralente insulin, is absorbed very slowly due to its zinc 
crystalline form. It has an onset time of 6-10 hours and is effective for 18-24 hours (DeWitt and 
Hirsch, 2003). The different forms of insulin can be administered separately, but administration 
of a mixture of the short and intermediate or rapid and long-acting forms can result in more 
normal blood glucose levels in some patients (Insulin Administration, 2000). Premixed insulin 
preparations composed of proportions of NPH and regular insulin or NPH and insulin lispro are 
commonly administered as they can produce a more normal blood glucose concentration over 
long periods of time (Insulin Administration, 2000).  
2.2 Problems with Needles 
In patients with type I diabetes, subcutaneous administration involves an average of four 
daily injections with syringes of varying lengths, in addition to regular self-testing of their blood 
glucose levels (Mollema et al., 2001). Since adherence to insulin self-injections and self-testing 
are essential for glycemic control, poor patient compliance is a serious impediment to the 
effectiveness of insulin therapies. Blood-injection-injury phobias and anxiety can keep patients 
from administering their own injections, thereby increasing the likelihood of unwanted health 
complications (Mollema et al., 2001). Berlin et al. found that type I diabetes patients with poor 
glycemic control also exhibited high levels of anxiety and phobic symptoms (1997). These 




significant portion of type I diabetes subjects displayed high levels of anxiety in association with 
their insulin injections (1999). Mollema et al. attempted to estimate the magnitude of these 
blood-injection-injury phobias in patients receiving insulin treatments, and found that out of a 
research population of 1275 patients, 0.2-1.3% showed fears of self-injecting, and 0.6-0.8% 
showed fears of self-testing (2001). These results indicate that while phobias and anxieties do not 
prevail among type I diabetes patients, a significant number of patients may only receive decent 
glycemic control at the expense of their quality of life (Mollema et al., 2001).  
 Another problem associated with injected insulin is variation in the actual insulin 
absorption. Numerous studies have documented differing rates of absorption among patients with 
type I diabetes. One study conducted by Binder demonstrated that radioactively labeled insulin 
showed absorption rates varying from 19-104% within different patients (1969). Lauritzen et al. 
also demonstrated that the absorption rate among different patients varied by 50% (1982).   
Variations in absorption have also been shown to occur within an individual. According to the 
Health Technology Assessment, absorption rates in a single patient can vary by about 25% 
(Colquitt et al., 2004).  A study by Heinemann corroborated this data and found that after 
subcutaneous insulin injection, the action of regular insulin within one individual varies by 15 to 
25%, and the action of long-acting insulin varies by 25-35% (Heinemann, 2002). Lauritzen et al. 
also found that absorption within an individual varies by 25% (1982).  
Further complicating the issue, Heinemann points out that variations in insulin absorption 
are likely greater than the reported 15-35%, as variations in patients leading normal daily lives 
are likely to be greater than variations in patients living under controlled experimental conditions 
(Heinemann, 2002).   Many factors, such as the site and depth of the injection, the amount of fat 




the skin, influence the absorption of insulin and could contribute to the aforementioned 
variations (Chen et al., 2003). This is a serious problem with subcutaneous injections, as the 
variations can lead to dosing problems; too little insulin can lead to hyperglycemia while too 
much can result in hypoglycemia. Intra-individual variation in insulin absorption may be 
responsible for the daily variation in blood glucose levels and is a serious impediment to the 
control of diabetes (Lauritzen et al., 1982).  
In addition to the risks associated with phobia, poor patient compliance, and variations in 
absorption rates, the reuse of needles or syringes among patients introduces concerns of sterility 
and raises the risk of infection. While manufacturers recommend that the disposable needles and 
syringes be used only once, some patients claim that they find it practical to reuse needles 
(Insulin Administration, 2000).  
2.3 Alternatives to Subcutaneous Injection 
 The aforementioned problems with needles have led researchers to investigate a variety 
of alternative mechanisms that could replace subcutaneous injections. While some of the 
following methods have reached the market and others have not, none of them have been widely 
accepted as a suitable substitute for needle-based methods. 
2.3.1 Insulin Pump 
 One treatment method that has been presented as a replacement to daily insulin injections 
is that of continuous subcutaneous insulin infusion, commonly known as the insulin pump. The 
principle of the technology is simple; a small pump, weighing around 400 grams and containing 
a cartridge of insulin, is connected to a catheter that is inserted into the tissue (Lenhard & 




throughout the day, decreasing the likelihood of the unexpected health complications (Biscoff et 
al., 1994). Also, the pump has the capability to deliver varying amounts of insulin throughout the 
day, allowing patients more freedom in their activities such as “skipping or delaying meals, 
sleeping late on weekends, or engaging in vigorous exercise” (Lenhard & Reeves, 2001). 
 Unfortunately, there are also several drawbacks to insulin pump therapy. Primary among 
them is the high risk of infection that exists at the point where the catheter enters the body; 
values as high as 11.3 events per 100 years of patient follow-up have been reported by the 
Diabetes Control and Complications Trial Research Group (1995). There is also the possibility 
that the catheter or tubing can become occluded or that the pump can exhaust its insulin supply. 
Since the pump relies solely on short-acting insulin, any break in delivery can result in rapid 
increases of blood glucose levels (Castillo et al., 1996). Finally, and most significantly for our 
team, the costs associated with an insulin pump are much higher than other methods for glucose 
control. The startup costs are about $5,000 with an additional annual cost of $1,500 (Lenhard & 
Reeves, 2001). This is prohibitive for many patients and does not meet the team goal for an 
alternative that can be widely accessible. 
2.3.2 Jet Injection 
 Another method that has received considerable attention from researchers is that of jet 
injection. The jet injection technology was aimed at relieving patients’ reluctance to accept 
multiple painful injections of insulin and their difficulty in synchronizing carbohydrate and 
insulin absorption (Alberti et al, 1980). These devices use compressed springs or gasses to shoot 
liquids containing the molecules of choice at high velocity into the skin, and have been shown to 
penetrate the stratum corneum (Stachowiak et al., in press). While physiologically significant 




do not currently outweigh the costs. Bruising and pain have been reported by humans who have 
undergone jet injection therapies due to the deep penetration of the jets (Mitragotri, 2006), and 
delivery of insulin is not improved in comparison with subcutaneous injection (Anderson et al., 
1980). While microjet injectors aim to minimize patient discomfort, they have yet to be 
standardized and the majority of current research utilizes custom-made technology. There are 
currently a number of jet injectors available commercially, but a quantitative understanding of 
the energetics of jet injection is still lacking (Mitragotri et al, 2004). 
2.3.3 Inhalable Insulin 
 The idea of administering insulin in an inhalable form, similar to that found in inhalers 
used by asthmatics, blossomed in 2006 when Pfizer presented Exubera® to the market. Exubera 
was designed to deliver short-acting insulin to accommodate increases in glucose levels 
following meals. Like an asthma inhaler, Exubera required the patient to pump the handle, 
aerosolizing the insulin, and to then take a normal breath from the inhaler (D’Arrigo, 2007). 
While some initial reports from patients trying inhalable insulin products were positive (West, 
2001) and others were negative (Weintrab, 2007), Pfizer decided to market their product. After 
approximately one year, Exubera was withdrawn from the market for a 2.8 billion dollar loss by 
Pfizer (Weintrab, 2007). Use of the device had been associated with decreased lung function 
(D’Arrigo, 2007), and the device itself was described as “cumbersome” by diabetics who used it. 
As a final blow, a treatment regimen based on Exubera was estimated to cost 30% more than a 
regimen based on injections (Weintrab, 2007). 
 Currently, there are no other forms of inhalable insulin on the market. In 1998, Eli Lilly 
and Co. announced that it was developing an insulin product based on the asthma inhaler, 




insulin through the inhaler (Smith, 1998). However, in 2008, Eli Lilly announced that the trials 
of its insulin product were going to be cancelled due to high costs of production (Dagher, 2008). 
2.3.4 Oral Insulin 
 Researchers have also investigated the possibility of administering insulin in a pill form 
similar to a vitamin supplement. The benefits of this approach are easy to see, as the patients’ 
discomfort would be much less than it would be with needles, and pills are an easy and safe 
treatment that could travel with a diabetic. For these reasons, scientists have suggested that orally 
administered insulin would be advantageous to traditional injection methods (Ghilzai, 2003). 
Barclay found that “oral insulin was safe, well tolerated, more effective than placebo, and as 
effective as subcutaneous regular insulin at controlling postprandial glycemia” (2003). 
Additional support for these results has been presented by Xie et al. (2008), who found that 
blood glucose levels could be drastically reduced in diabetic mice when they were fed 
genetically altered rice seeds. The rice plants were mutated so that their seeds contained high 
levels of human insulin-like growth factor 1, a necessary precursor for insulin release in the body 
which could in turn reduce blood sugar levels. 
Unfortunately, there are several challenges associated with delivering insulin through the 
gastrointestinal tract. Native proteolytic enzymes do not discriminate between insulin and other 
ingested proteins when degrading the contents of the tract, and permeation through the tract itself 
can be insufficient for insulin delivery (Hamman et al., 2005). Existing research has addressed a 
number of methods to circumvent these pitfalls such as absorption enhancers to increase the 
amount of insulin that passes through the intestinal epithelium, enzyme inhibitors to prevent 
insulin degradation, and targeted delivery systems that attempt to localize insulin to the areas of 




however, oral insulin has not yet reached its potential as a viable alternative to needle-based 
administration of insulin. 
2.3.5 Microneedles 
 Another transdermal alternative that has received attention in recent years is 
microfabricated needles, or more conventionally, microneedles. Microneedles used in 
transdermal drug delivery are typically presented in arrays of five to fifty needles whose lengths 
usually range between 500 and 1,000 micrometers (one half to one millimeter) (Gill et al., 2008). 
They can be either hollow, allowing substances to be pumped through them, or solid, with the 
substance to be transferred coating the needles’ surfaces (Prausnitz & Langer, 2008). Drugs, 
proteins, and DNA particles have all been tested with relative success using these methods (Gill 
& Prausnitz, 2007). In fact, several studies have indicated that microneedles can be used to 
facilitate the delivery of physiologically significant amounts of insulin. Among these are 
McAllister et al. (2003) and Martanto et al. (2004), both of whom recorded decreases in rat blood 
glucose levels following microneedle treatment.  
 While microneedles show promise as a potential means of transdermal drug delivery, 
several drawbacks still exist with the technology. Primary among these is that fact that the 
protection provided by the stratum corneum is compromised, allowing undesired agents to enter 
the body after the target drug has been delivered (Cevc 2003). In addition, it is also possible for 
microneedle tips to break off from the patch and become lodged in the skin, again compromising 
the integrity of the skin barrier (McAllister et al., 2003). In addition to these negatives, we found 




2.3.6 Transdermal Patches 
There are currently numerous drug-delivery patches available on the market today. In 
2003, it was reported that patch sales totaled $1.2 billion. Current transdermal delivery systems 
are designed to provide continuous controlled release of medication through intact skin, therefore 
providing a constant level of a drug in the blood (Egan, 2003).  
2.3.6.1 Birth Control Patch 
The birth control patch, Ortho Evra, is for the prevention of pregnancy in women who 
want to use a transdermal patch as contraception. Developed by Ortho-McNeil-Janssen 
Pharmaceuticals, Ortho Evra was approved by the Food and Drug Administration in 2002. Ortho 
Evra’s website states that the patch is worn on the body and works by delivering a continuous 
level of hormones (progestin and estrogen) into the bloodstream through the skin. Progestin and 
estrogen prevent ovulation by preventing the ovary form releasing an egg to be fertilized (“Ortho 
Evra, the Patch”). These hormones also thicken the cervical mucus, making it more difficult for 
sperm to enter the uterus. In addition, the endometrium, the mucus membrane that lines the 
uterus, is affected and reduces the chance of implantation (“Ortho Evra, the Patch”). 
A new patch is placed onto the body once a week for three weeks in a row each month. 
The site advises that the patch is placed on one of four places: buttocks, upper torso, abdomen, 
upper outer arm. The patch contains three layers: the first layer is an outer protective layer of 
polyester, the middle layer is a medicated adhesive and the third layer is a clear polyester release 
liner, which is removed just before application (“Transdermal Contraception,” 2005). 
The birth control patch has been relatively successful. In fact, women reported using the 




women used the patch correctly in 88% of their cycles compared with 78% of cycles among oral 
contraception users (“Transdermal Contraception,” 2005). 
However, there has also been some controversy surrounding the patch. The site mentions 
that a person using Ortho Evra is exposed to about 60% more estrogen than a person using the 
typical birth control pill, which increases the risk of side effects. And in January 2008, the FDA 
approved an updated additional warning label to the Ortho Evra patch, to clearly state that 
women using the patch may have a higher risk of developing venous thrombo-embolism (blood 
clots in the legs and/or the lungs) because of their receiving a higher dose of estrogen (Kuehn, 
2008). This is a result of study conducted by the Boston Collaborative Drug Surveillance 
Program (Kuehn, 2008). 
2.3.6.2 Nicotine Patch 
Nicotine patches deliver nicotine patches at a relatively steady rate and are applied once 
daily (Nicotine Delivery Systems). The nicotine patch is designed to satisfy smokers’ nicotine 
cravings. Each 2 inch adhesive patch delivers a controlled release of nicotine for 24 hours. It is 
used as a temporary aid to help one quit smoking by reducing nicotine withdrawal symptoms. 
The Nicoderm website states that the patch uses a patented technology called 
SmartControl™ on the dermal side of the patch. SmartControl™ ensures that all of the nicotine 
will not be delivered at once or run out too soon. 
Experiments have been performed investigating the success rate of using the nicotine 
patch in order to quit smoking. One study, done in 2008, examined whether adherence with daily 
nicotine patch wear was associated with improved rates of smoking abstinence. The double-blind 
study had randomized subjects receive either an active nicotine patch or a placebo under 




adherence to daily nicotine patch wear within the first three weeks of treatment was associated 
with an improved likelihood of achieving smoking abstinence at six weeks. 
2.3.6.3 Nitroglycerin Patch 
 Transdermal nitroglycerin is indicated for the prevention of angina pectoris due to 
coronary artery disease. The pharmacological action of nitroglycerin is relaxation of vascular 
smooth muscle and consequent dilatation of peripheral arteries and veins. Dilatation of the veins 
promotes pooling of blood and decreases the return to the heart, which reduces left ventricular 
end-diastolic pressure and pulmonary capillary wedge pressure. In terms of transdermal 
nitroglycerin, the MINITRAN™ Transdermal Delivery System is currently available today. It is 
designed to provide continuous controlled release of nitroglycerin through intact skin. The rate of 
release of nitroglycerin is linearly dependent upon the area of the applied area (Daily Med).  
There have been recent studies which show that the transdermal administration of 
nitroglycerin could be used as treatment for pregnant patients with preeclampsia. Transdermal 
nitroglycerin patches deliver nitric oxide, which is a potent vasodilator and an inhibitor of 
platelet aggregation. This allows more blood to flow through the blood vessels easier. In 
pregnancy, nitric oxide is synthesized in several uteroplacental tissues and in endothelial cells of 
umbilical vessels. A deficiency in nitric oxide is a factor in patients with preeclampsia. In a study 
performed on pregnant patients with preeclampsia who had increased uteroplacental impedance, 
the delivery of nitroglycerin through transdermal technologies resulted in the decrease of uterine 





2.3.7 Technologies in Progress 
Currently, there are two main non-invasive insulin delivery technologies undergoing 
phase 2 clinical trials. Both the insulin gel and ultrasonic insulin patch have the potential to 
capture the market niche our team hopes to dominate with our technology. Therefore, all of our 
team's future works must take care to create a technology that distinguishes itself from these 
competitors. In Australia, Phosphagenics Limited has patented a gel delivery system for insulin, 
and Pennsylvania-based Encapsulation Systems, Inc has developed an ultrasonic patch to replace 
the catheter in an insulin pump. 
Phosphagenics Limited initiated phase 1B clinical trials for their transdermal insulin 
product, and has since reported positive results. The trials utilize Phosphagenics' patented TPM-
02 delivery system. The system has been adapted for use with both short and long term insulin 
and presents both types of the drug in gel form. Phase 1A trials in 2006 showed that the insulin 
gel was able to effectively deliver insulin through the dermal tissue and into the bloodstream, 
resulting in significantly lowered blood glucose levels in human test subjects. The 1B trial 
provided supporting data necessary for a new drug application from the U.S. Food and Drug 
Administration (PR Newswire, 2007). In 2008, the company initiated phase 2 clinical trials in 
type I diabetic patients (Phosphagenics, 2008). 
Phosphagenics' proprietary TPM delivery system is a patented transdermal carrier 
technology that works with the skin's natural transport mechanisms. It facilitates the transport of 
variously sized molecules through the tissue without compromising the integrity of the dermis as 
a barrier to harmful environmental elements. The TPM-01 system delivers small molecules such 
as morphine and testosterone, while the TPM-02 system delivers both small and large molecules, 




Encapsulation Systems, Inc has also put a breakthrough technology for insulin delivery 
into the development pipeline -- an ultrasonic patch the size of a matchbook for use with an 
insulin pump. The technology was originally developed by a team of engineers at Penn State, 
which ascertained that the sonic patch could safely deliver insulin to rats (DeNoon, 2002). 
Encapsulation Systems, Inc has taken the technology a step further and developed the U-Strip 
(TM) Insulin Patch. The patch uses an alternating sonic transmission to dilate the pores of the 
skin, allowing large molecules such as insulin molecules to be effectively deposited within the 
dermis, allowing for direct bloodstream absorption. The patch consists of three major 
components: a patch designed to contain the target drug, the programmable ultrasonic 
transmitter, fitted above the patch, and a rechargeable battery system. The U-Strip (TM) Insulin 
Patch can be used for both basal and bolus doses of insulin. However, this technology is 
currently in phase 2 clinical trials and has not yet been approved by the FDA (Marketwire, 
2007). 
2.4 Liposomes 
2.4.1 Define Vesicle 
At the simplest level, a vesicle is nothing more than a bubble formed by a special type of 
molecules called phospholipids. The basic structure of a phospholipid can be seen in Figure 3-A.  
The top, circular portions (called heads) of these molecules contain electric charges which 
interact strongly with each other and with water. The presence of charges in the molecules makes 







Figure 3: The formation of a vesicle from phospholipid to belayed to sphere 
(adopted from Wang, Inex Pharmaceuticals Corporation). 
      A.     B.              C. 
 
 
The lower portions (tails) of the phospholipid are formed primarily from electrically 
neutral elements which react with each other more than they do with water. These are described 
as nonpolar because they have a neutral charge so they are less likely to interact with charged 
molecules (as in the interaction between a magnet and a non-charged piece of metal such as a 
quarter). Because it is energetically favorable for nonpolar groups to associate with each other in 
a polar solution, phospholipids spontaneously arrange themselves so that their tails are aligned 
next to one another. 
When both the head and tail ends of the phospholipids align with other polar and 
nonpolar ends, respectively, a sheet such as the one in Figure 3-B is formed. The symmetric 
arrangement of two layers (known as a belayed) is a further result of the interactions between 
heads and tails. The sandwich is formed because each portion of the molecule is surrounded by 
an environment where the tails are exposed only to tails, while the heads are exposed only to 




The final, bubble-like structure of the vesicle is a result of the work of these same forces. 
By closing the membrane into a sphere, any edges where the nonpolar tails would be exposed to 
the solution are eliminated (Figure 3-C). As with the previous steps, this arrangement occurs 
spontaneously in solution because of the inherent electrochemical properties of a phospholipid. 
2.4.2 Define Liposome 
A liposome is simply a lipid vesicle that encapsulates an aqueous solution (Williams, 
2003). While they are the most common component of biological membranes, phospholipids are 
not necessarily the only types of molecules that can participate in vesicle formation. Other 
molecules, such as cholesterol, have similar polar and nonpolar components that allow them to 
participate in vesicle formation (Vemuri & Rhodes, 1995).  
2.4.3 Define Surfactant 
 When liposomes are formed in the laboratory setting, the experimenter can choose what 
components are to be included in the membrane. By incorporating different types of molecules in 
addition to phospholipids, scientists can drastically alter the properties of the vesicles that are 
formed. Additional agents can be incorporated in order to add charge to a membrane, to adjust its 
flexibility or stability, or to make it respond to specific environmental stimuli. 
 One class of molecules that are commonly added to liposomes are known as “surface 
active reagents,” or “surfactants” for short. Inclusion of surfactants in a liposomal membrane 
disrupts the native structure of the phospholipids, thus increasing the flexibility of the membrane 
(hence, these liposomes are called ‘elastic’). To picture this, imagine that all of the phospholipid 
heads are cubes. Alone, they fit rather tightly together, side by side. When cylindrical surfactants 




however, there will be areas where a cube is bordered by a cylinder rather than by another cube. 
The resulting disorder is similar to that induced by surfactants in a phospholipid membrane. 
 A large number of surfactants have been investigated by scientists. Cevc et al. (1998) 
describe how the combination of multiple elements with different characteristics allows vesicles 
to adapt to stresses (such as squeezing through the tight pores in the skin). This “self-
optimization” can occur because it is energetically favorable for all of the least stable molecules 
to associate at the stress point on the liposomal membrane. It has been argued that the localized 
increase in concentration of unstable molecules allows the vesicle to deform and enter the pore 
far enough to be drawn completely through (Cevc 2003). 
 Unfortunately, this increase in flexibility comes at a price. As the flexibility of a liposome 
increases, its ability to effectively hold its contents decreases. This results in a lower 
encapsulation efficiency (how much drug is actually held in the liposomes when they are 
created). Furthermore, the extreme deformations that occur while a liposome passes through a 
small pore result in some loss of carrying ability (Cevc et al., 2002). 
 An additional use of surfactants is to enhance the carrying abilities of liposomes for 
certain molecules. Three surfactants, sodium cholate, sodium deoxycholate, and Tween 80 were 
studied by Lee et al. (2005) in regards to their efficiency at encapsulating DNA (which carries a 
negative charge). Since Tween 80 is a neutral molecule, it was unable to complex with the DNA 
and was the worst performer of the three tested. However, this specificity can also work to the 
advantage of the experimenter. 
 Hayashi et al. (2003) attempted to use liposomes to deliver phosphatidic acid, a small 
fatty acid, to Chinese hamster ovary cells. If present in solution on its own, phosphatidic acid 




neutral Tween 80, the authors successfully prevented this undesirable reaction from occurring. In 
a similar experiment, Sudimack et al. (2002) used Tween 80 to stabilize their liposomes so that 
they would not be adversely affected by the proteins found in blood plasma/serum. 
2.4.4 Conflicting Studies of Skin Penetration by Liposomes 
 One of the primary issues concerning the effectiveness of liposomes as a means of 
transdermal drug delivery is the lack of standardization that is employed throughout the field of 
research. A wide variety of surfactant combinations as well as the use of different model systems 
makes comparing different experiments difficult. Nonetheless, some consistent results have been 
obtained. 
 In their studies using both mice and humans as model systems, Cevc et al. (1998) 
observed similar trends in the effectiveness of liposomes at delivering insulin through the skin. 
This is significant because mice, unlike humans, are almost completely covered by hair follicles 
that could be serving as natural channels to allow liposomes to penetrate deep into the skin. The 
findings of Cevc and his colleagues indicate that the mouse can be used as an accurate model 
system despite this physiological disparity. 
 A study by Honeywell-Nguyen et al. in 2002 showed that rigid conventional 
(phospholipid only) liposomes did not penetrate the skin. In fact, intact vesicles were not even 
found at the skin’s surface. This indicated that all of the vesicles either fused together or were 
ruptured by the forces acting at the skin’s surface. While some level of fusion is expected, too 
much vesicular conglomeration will increase the size of the liposomes to the point that they will 
no longer be able to penetrate the skin. This result is corroborated by Zellmer et al. (1999), who 




that individual molecules could induce small barrier changes in the skin. However, these changes 
were deemed insignificant by the researchers. 
This opinion is not universal, as some believe these barrier changes may actually have 
significant consequences. According to Bouwstra et al. (2002), proteins do not play a large role 
in deciding the organization of the stratum corneum. The authors found that model systems 
consisting solely of various fats (lipids) were remarkably accurate when compared with real 
stratum corneum. As such, anything that disturbs lipid organization can be considered significant 
in terms of skin permeability. In a study described previously, Honeywell-Nguyen et al. found 
that micelles (spheres similar to liposomes but with only one layer of phospholipids) disrupted 
the lipid portion of the stratum corneum. While the authors describe this in a positive light 
(micelles as “permeation enhancers”), the disruption of the stratum corneum could allow 
undesirable foreign molecules such as viruses or bacteria to enter the skin along with vesicles. 
2.4.5 Evidence Supporting Skin Penetration by Liposomes 
 Opposing the studies denouncing skin penetration by liposomes is an abundance of 
evidence indicating that liposomes (particularly elastic liposomes) can serve as effective 
transdermal drug carriers. According to Cevc, et al. (1998), once the liposome reaches a certain 
distance within a pore, it is effectively sucked through by a transdermal osmotic force. To 
support this theory, the authors used Transfersomes®, a specific type of elastic liposome, to 
deliver insulin to mice. They found that within two to four hours of such attempts, the glucose 
levels of the mice decreased by 20-30%. 
 The authors were able to confirm that this decrease in blood sugar was a direct result of 
the transdermal insulin because the concentration of C-peptide, a protein produced in 




in insulin). Further support for this claim comes from the in vitro portion of the same experiment. 
It was found that ninety percent of Transfersome-associated insulin remained after passing the 
liposomes through an artificial membrane barrier. As a result of their findings, the authors 
propose that their compound could be applied to forty square centimeters of skin (roughly the 
size of a palm) over the course of a day for treatment of Type I diabetes (Cevc 1998). 
 These findings are supported by Honeywell-Nguyen et al., who found that elastic vesicles 
can penetrate deep into human skin within one hour (2002). Freeze frame electron microscopy 
was used to visualize intact vesicles in channel-like regions that ran well below the surface of the 
skin. These channel-like regions were also present in control subjects, indicating that they are a 
natural phenomenon not created by the application of liposomes. 
 Further support for the beneficial contribution of liposomal flexibility to skin penetrance 
and ultimately drug delivery is presented by Kujik-Meuwissen et al. (1998). The authors found 
that fluorescently labeled vesicles in their liquid state (which are more flexible) penetrated 
deeper into rat skin than their gel state (more rigid) counterparts. This study also examined the 
penetrance of micelles into the skin and surprisingly found that they did not penetrate as well as 
the more flexible vesicles. 
2.4.6 Liposome Stability and Penetrance 
Various surfactant formulations and concentrations can alter the state of liposomes in 
solution. One of the primary ways in which these changes take place is the formation of micelles 
that can occur following the addition of surfactant to a liposome formulation. The results of a 
cryo-transmission electron microscopy study, which allows an extremely close view of a sample 




increased the resulting vesicles decreased in size, tended to open to solution more often, and 
collapsed more frequently into cylindrical and spherical micelles (Vinson et al. 1989).  
Walter et al. (1991) provide further evidence of the transition that occurs between 
liposome and micelle when surfactants are present. They found that as the amount of surfactant 
was increased liposomes would be destabilized from hollow spheres into flat sheets, causing 
cylindrical micelles to break off from the edge of the sheets. This disintegration of the elastic 
liposomes results in smaller vesicles, which have been reported to have better penetrative 
properties than their larger counterparts. Verma et al. (2003) reported that liposomes with a 
radius of 120 nanometers were much more effective at traversing human abdominal skin than 
larger vesicles.  
The fact that the sizes of the liposomes in a solution have a significant effect on 
penetration ability means that the size of a liposome over time is an important factor to consider 
in the study of liposome-based drug delivery methods. One group, led by Gritand (1992) used an 
excessively warm environment (60o C) to simulate the aging process, which results in partial 
hydrolysis of the lipids and ultimately membrane degeneration. They found that while the 
liposome size did not change appreciably over time, the stability (gauged by the capacity of the 
liposomes to keep a substance in solution outside of the membranes) decreased significantly after 





3.1 Liposome Size and Stability Studies 
3.1.1 General Methods 
 
 The objective of this experiment was to assess the stability and rigidity of liposomes over 
time. The first step in this process involved the construction of both rigid and flexible liposomes 
with different compositions of egg phosphatidylcholine (egg PC) and Tween 80 surfactant. We 
used a stainless steel extruder to filter the liposomes through polycarbonate membranes with 
defined pore sizes in order to produce a homogenous population of vesicles. Next we measured 
the mean radius of our liposome samples using dynamic light scattering. DLS relies on the 
scattering of light when a laser beam passes through particles in a colloidal suspension. 
Typically, such particles undergo random thermal motion, known as Brownian motion, which 
results in fluctuations of light intensity detected by the DLS machine. A computer program was 
used to calculate these size distributions based on the intensity fluctuations of the particles in a 
sample. 
 During the first trial, the temperature of the sample chamber within the DLS machine was 
not taken into consideration. This resulted in extreme fluctuations in size over the two-week trial. 
After trouble-shooting our experimental protocol, we concluded that temperature of the DLS 
needed to be strictly regulated and kept constant during size measurements to ensure uniform 
conditions throughout the experiment. Ultimately, we decided to make measurements at room 




Both a two-week trial and a six week trial were conducted for the size measurements of 
the different molar ratios. The same revised protocol accounting for constant temperature was 
used for both trials. 
3.1.2 Experiment Protocol 
 On the first day of liposome preparation, 7.4 grams of 20mg/ml egg phosphatidylcholine 
(egg PC) in chloroform solution was measured, placed into a large, glass vial, and dried with 
nitrogen at 6-7 psi until there was no longer any visible liquid. This process took approximately 
twenty minutes. The sample was then placed into the vacuum desiccator.  
 On the second day, the egg PC was removed from the vacuum desiccator. Tween 80 
surfactant, and ten grams of de-ionized water were added to the glass vial, and the solution was 
stirred for thirty minutes. The solution was then frozen and thawed six consecutive times to 
ensure uniformity in the liposomes. Each time, the vial was dipped into liquid nitrogen for 
approximately 15 seconds, and then immediately thawed in a beaker of warm water. After each 
thaw, the warm water was replaced. 
 The sample was then forced through two 100 nm polycarbonate membranes in a stainless 
steel extruder ten to twelve times. After passing through these membranes, the sample was 
immediately transferred back into the vial, while simultaneously ensuring that no bubbles were 
introduced into the sample, as this could have affected the DLS measurements. Afterwards the 
vial was wiped free of smudges and placed into the DLS machine. 
Once inside the sample chamber of the DLS machine, the temperature control was set to 
twenty-five degrees Celsius. The duration between size measurements was then recorded, as well 
as intensity, coherence, mean radius with standard deviations, and the polydispersity index. This 




 After collecting the size distribution measurements, the sample was separated into two 5 
milliliters aliquots. The first aliquot was weighed and prepared for a flexibility test, while the 
second aliquot was stored for long-term size measurements. Aliquot one was then extruded 
through three 50 nm polycarbonate membranes, and the time taken for extrusion and mass of the 
extruded sample were recorded. The size distribution of this sample was then measured again. 
These values were used to calculate extrusion rate and flexibility index of our samples. The mean 
radius of liposomes in aliquot two was measured regularly for the duration of the experiment. 
 Upon completion of two weeks of measurements, the second aliquot was extruded 
through three 50 nm polycarbonate membranes. The duration of the extrusion, mean radius of 
vesicles before and after extrusion, as well as the weight of the sample before and after extrusion 
were recorded to calculate the flexibility index of the sample after the two-week time period. 
 The same experiment was conducted across a span of six weeks. Measurements were 
taken of the samples every other day over the course of the first two weeks, and then once a 
week after that. For the two-week trial we prepared vesicles with 0% surfactant, 25% surfactant, 
and 50% surfactant by molar ratio. In the six-week trial, we tested an additional liposome sample 
with 75% molar ratio surfactant. 
 The molar ratios used are summarized in the following table: 
Table 1: Liposome Compositions 
Molar Ratio of Tween 80 to Egg PC Tween 80 (grams) Egg PC (grams)
1 to 3 0.0570 7.40
1 to 1 0.1729 7.40
3 to 1 0.5188 7.40






3.1.3 Data Analysis 
 For both the two and six week experiments, fluctuations in the mean radius of each 
sample were graphed with Microsoft Excel. The extrusion rate and flexibility of our various 
samples was also calculated with the following equation adapted from Hiruta et al. (2006):  
Elasticity = JFlux x (rv/rp)2
JFlux represents the rate of penetration through a permeability barrier in units of grams per 
second. This value was calculated as the mass of sample per unit time that was extruded through 
50 nm membranes. 
rv is the mean radius of the vesicles after extrusion. This value is equivalent to the mean radius of 
the sample measured by the DLS after the final extrusion. 
rp is the radius of the pores in the barrier, which in our case was 50 nm.  
3.2 Gel Permeation Studies 
3.2.1 Preparation of Slides 
 A custom slide setup was designed and constructed to allow for the preparation of gels 
directly on microscope slides.  A microscope slide was cut ½ inch from the ends, generating two 
½ inch pieces. These pieces served as spacers that were ultimately sandwiched and fixed with 
epoxy between two new slides. Finally, the gap at the bottom of the two slides was sealed with 
epoxy and the slides were allowed to dry overnight. This construction created an opening at the 
top of the slides 1 - 1.2 mm thick that could be filled with gel.  
 Agarose (Fisher Scientific Co.) was used to make gels that were 1.3% agarose by weight.  




obtain the mass of agarose that should be added to create a gel that was 1.3 wt% agarose.  The 
actual numbers used can be seen in Table 2. 








Water (g) Agarose (g) True Gel 
Percentage
Actual values of gel compositions
 
         Mean gel composition was 1.30 wt% with a standard deviation of 0.003.   
The water and agarose were microwaved for 50 seconds and a micropipette was used to fill the 
slide construction with the liquefied gel.  A 12 mm spacer was then inserted into the middle of 
the cooling liquid and the whole preparation was placed in 4°C for 4 minutes.  The spacer was 
then removed, leaving a well in solidified gel. The preparation was wrapped in parafilm and used 


































The red area in this image is the well after it has been filled with DII-Liposome solution.  The 
lighter gray rectangle in the middle of the slide construction is the area of agarose gel.  
 
These slide constructions were important because they allowed for the preparation of gels 
directly on microscope slides, which in turn allowed for convenient transfer of the gel and 
vesicles to the microscope for image capture. 
3.2.2 Permeation Studies 
 In all permeations studies 70 μl of liposome-DII solution were added to the well in the 
gel.  The slide preparation was then placed under the fluorescent light and images were captured 
at 30, 60, 90, 120, 180, 240, 300, 360, 420, 480, 540, and 600 seconds.  All images were taken at 
room temperature.  
3.2.3 Image Analysis  
 Images were analyzed with ImageJ, free imaging software provided by the National 
Institutes of Health.  With the software’s line drawing tool, a single line was drawn from the top 
of the image, corresponding to the top of the well on the microscope slide, to the bottom of the 




50% surfactant onto the gel, and can be seen in Figure 5.  The red arrow represents the direction 
of liposome migration.     
Figure 5: Example of images visualized with Image J 
 
 
The program uses the red line to construct a profile plot of the fluorescence intensity (gray scale 
value) as a function of distance from the top of the image to the bottom of the image.  A sample 
graph can be seen in Figure 6, with the red arrow representing the direction of liposome 
migration.  
Figure 6: Example of profile plot of fluorescent intensity as a function of distance 
 
 
The x and y coordinates (position in inches and gray value, respectively) for the graph 





3.2.4 Determination of Diffusion Coefficients and Graphs of Diffusion Coefficients 
Data obtained from the ImageJ photographs were fitted to the solution of Fick’s Law of 
Diffusion (see below) with a least-squares regression done using the mathematical software 




Fick’s Law of Diffusion 
 
                                               
 
One Dimensional Solution to Fick’s Law of Diffusion 
 
A least squares regression fits a curve to a set of data by minimizing the square of the 
difference between the value of the dependent variable and the value given by the curve fit. Data 
was inputted from a text file, and through a series of matrix manipulations and minimizing 
functions, we determined the diffusion coefficient for each set of data points.  
All the diffusion coefficients were compiled and plotted over time in Microsoft Excel. 
Using their regression package, we fitted our data to the power law and recorded the appropriate 
coefficients. We also plotted our diffusion coefficients using the Excel graph functions. 
3.2.5 Modeling Methodology 
Using the steady-state value of the equilibrium constant, the final diffusion coefficient 
value, we created an iterative model using Excel describing drug depletion from a patch reservoir 
and delivery through a skin barrier into the subcutaneous tissue. The model works by 




those amounts into determining the delivery rate for that interval. The delivery rate then affects 
the amount of insulin in the reservoir for the next time interval and etc. 
The model starts with the diffusion coefficient, a patch volume and surface area, the 
barrier thickness and an initial concentration of insulin in the patch. The diffusion coefficient is 
taken from the plot of diffusion coefficients over time for 50% surfactant liposomes. After the 
initial drop, the diffusion coefficients eventually level off to a near-constant value and that value 
was taken to be the coefficient for our model. The patch volume and surface area are arbitrarily 
chosen values based on typical and reasonable dimensions for drug patches. The barrier 
thickness was chosen to reflect the more tortuous pathways of the skin compared to agarose gel. 
The initial concentration of insulin was calculated from the assumptions of 10% vesicle loading 
efficiency and of each loaded vesicle only having one repeating unit of the standard insulin 
crystal. Vesicle concentrations were calculated from initial lipid concentrations, our vesicle size 
study, and the work of C. Huang et al. on geometric packing of egg phosphatidylcholine vesicles 
(1978). 









From the concentration, flux is calculated by multiplying the diffusion coefficient with 
the derivative of the concentration profile, which in this case is just the concentration divided by 




concentration by multiplying it with the volume of the patch. Flux is then multiplied by the area 
of the patch that is in contact with the skin, which gives the delivery rate. The new mass of drug 
in the patch for the next time iteration is then calculated by subtracting the delivery rate. From 
there, a new concentration can be calculated and then a new flux can be calculated, and etc. 
The results were plotted using Excel’s graphing function. 
3.2.6 Model Assumptions 
1. The drug well in the patch is well mixed and uniform at within time intervals. 
2. The steady-state between time intervals is reached in a short amount of time 
compared to the time interval 
3. The drug, when it reaches the end of the barrier, is removed immediately by the 
blood stream and does not build up outside the barrier. 
4. The model is based on data collected for agarose gel, which is the synthetic model 
for the skin. Agarose and skin are assumed to behave similarly for this model 
5. The model also assumes that a patch of the given dimensions can be made 
3.2.7 Implications of the Assumptions 
Our team made simplifying assumptions in order to complete a ball-park assessment of 
the transdermal drug delivery technology using the vesicles we had chosen. If further study is 
warranted, a more detailed and refined solution can be performed at the cost of more time and 





Assumption 1:  The theoretical patch is well mixed. 
Assuming this allows for a simpler solution to Fick’s law of diffusion. It also allows us to 
simply subtract the amount delivered from the drug well. Making this assumption will artificially 
increase the amount of drug delivered in our model compared to the amount that can be delivered 
in a real patch. In a real patch, the drug concentration within the drug well will also be at a 
gradient and will be less than a well-mixed (average) value. Having a lower drug concentration 
at the point of contact with the skin will decrease the rate of diffusion through the skin. 
Assumption 2: A steady-state solution would be reached relatively quickly. 
Assumption 2 is made so that we could use an iterative procedure to estimate the solution 
of a time-dependent transient problem. Since the concentration of the well is only changing by a 
very small fraction of the total concentration for each time interval, we assumed that a steady-
state solution would be reached relatively quickly and that it would be an acceptable estimation 
to the more difficult transient solution. Our assumption would artificially decrease the amount of 
drug delivered compared to a real patch. 
Assumption 3: Drugs delivered using the patch will immediately diffuse into the bloodstream. 
Once the drug defeats the skin barrier, it is assumed that it is immediately carried away 
from the end of the barrier by blood vessels that circulate blood through the body. Any 
accumulation at the end of the barrier would decrease the amount of drug that is delivered over 
time. Our assumption is true for insulin that reaches blood vessels but may not be true for insulin 
accumulating in the fat before reaching the blood vessel. Overall, this assumption artificially 




Assumption 4: Agarose gel is a good model for the skin. 
Since agarose and the skin have very different compositions and architectures we cannot 
truly judge the exact effects of using agarose as our skin model. We can safely assume that 
agarose will be easier to penetrate with vesicles than the skin. As such, using agarose gel as our 
skin model will artificially increase the amount of drug delivered by our model. 
Assumption 5: The dimensions of the patch we used for our model are reasonable and feasible to 
produce. 
4. Results 
4.1 Liposome Size and Stability Studies  
4.1.1 Vesicle Stability 
 We carried out two sets of experiments to test vesicle stability. In the first experiment, we 
measured the mean radius and scattering intensity of 0% surfactant liposomes, 25% surfactant 
liposomes and 50% surfactant liposomes over a two-week period.  In each of these 
measurements, we averaged three mean radius values and three intensity values. We then plotted 
the average mean radius (r) and average scattering intensity (I) versus days elapsed after vesicle 
preparation.  These graphs are presented below. 


























0% Surfactant 25% Surfactant 50% Surfactant
 





















 The data for both average mean radius and average scattering intensity display a clear 
trend that higher surfactant concentration leads to greater fluctuations in size. The radius of the 
0% surfactant liposomes started at an average of 39.3nm and only fluctuated between 41.1nm 
and 35.3nm, a range of just 5.8nm. Also, the radius of the 0% surfactant liposomes did not drop 
below 39nm until day 12 of the 14 day trial. The scattering intensity of the 0% surfactant 
liposomes started at 1.70*106 and fluctuated between 1.55*106 and 2.48*106, a range of 9.3*107. 
The radius of the 25% surfactant liposomes started at an average of 39.2nm and fluctuated 
between 39.2nm and 48.0nm, a range of 8.8nm. The scattering intensity of the 25% surfactant 
liposomes started at 1.56*106 and fluctuated between 1.01*106 and 3.13*106, a range of 
2.12*106. The radius of the 50% surfactant liposomes started at an average of 31.5nm and 
fluctuated from 31.5nm to 53.5nm, a much larger range of 22.0nm. The scattering intensity of 
the 50% surfactant liposomes started at 7.2*107 and fluctuated between 5.1*107 and 1.43*106, a 
range of 9.2*107. 
 In order to achieve a better understanding of the trends beyond two weeks, we then 
conducted a six-week trial of the same experiment. In addition to the formulation in the previous 
trial, we added a 75% surfactant liposome sample to the six-week study. Again, we averaged 
three mean radius values and three intensity values for each measurement. The graphs of these 
data are presented below. 













































0% Surfactant 25% Surfactant 50% Surfactant 75% Surfactant
 
Once again, the data for both average mean radius and average scattering intensity 
display a clear trend that higher surfactant concentration leads to greater fluctuations in size. The 
radius of the 0% surfactant liposomes started at an average of 37.6nm and only fluctuated 
between 35.7nm and 40.9nm, a range of just 5.2nm over the six-week period. The scattering 
intensity of the 0% surfactant liposomes started at 1.64*106 and fluctuated between 9.7*107 and 
1.73*106, a range of 7.6*107. The radius of the 25% surfactant liposomes started at an average of 
29.2nm and fluctuated between 29.2nm and 50.8nm, a range of 21.6nm. However, there was a 
large increase in size from day-zero to day-two after which the 25% surfactant liposomes only 
fluctuated between 43.9nm and 50.8nm, a range of 6.9nm. The scattering intensity of the 25% 
surfactant liposomes started at 9.5*107 and fluctuated between 6.4*107 and 1.83*106, a range of 




increased in five days to 55.4nm before dropping to 5.7 nm after 19 days and fluctuating between 
3.8nm and 6.3nm for the remainder of the six-week period. The scattering intensity of the 50% 
surfactant liposomes started at 3.5*107 and increased in two days to 1.43*106 before dropping to 
2.58*104 after 19 days and fluctuating between 1.99*104 and 2.8*104 for the remainder of the 
trial. The radius of the 75% surfactant liposomes started at an average of 16.6 nm, dropped to 
4.2nm after three days, and fluctuated between 3.9nm and 4.9nm for the remainder of the trial. 
The scattering intensity of the 75% surfactant liposomes started at just 8.88*104 and fluctuated 
between 2.27*104 and 3.43*104 from the third day to the end of the trial. 
4.1.2 Flexibility 
 The vesicles produced for the stability experiments were also tested for extrusion rate and 
flexibility both before and after a period of storage at room temperature. This period lasted 42, 
41, and 26 days for the 25%, 50%, and 75% surfactant samples, respectively. The mass of each 
sample was taken before and after extrusion and the extrusion time was recorded. The extrusion 
rate was calculated simply as the mass after extrusion divided by the extrusion time. Flexibility 
index was then calculated for each sample from the extrusion rate and vesicle size 
measurements. The data and graphs of extrusion rate and flexibility for all of our liposome 
formulations are presented below.  











0 n/a n/a n/a n/a
25 0.04539 0.005816 0.08268 0.0146
50 0.07168 0.03702 0.09691 n/a
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Initial Flexibility Index Flexibility Index after Storage
 
  
The 0% surfactant liposomes were not able to pass through the extruder, and therefore no 




flexibility index assumes that the vesicles passing through the extruder are larger than pores 
through which they traverse. Thus the vesicles must deform in order to squeeze through the 
extrusion pores. The flexibility index then is the extent to which liposomes can undergo this 
deformation. We did not calculate the post-storage flexibilities of the 50% and 75% liposomes or 
the pre-extrusion flexibility of the 75% liposomes because the mean radius of these samples was 
smaller than the radius of our extrusion pores. Thus these vesicles would have passed through the 
extruder without any deformation, and consequently our flexibility indices for these samples 
would have been invalid.  
Of the three samples, the 50% surfactant vesicles had the highest initial extrusion rate and 
flexibility at 0.07168 g/sec and 0.09691 g/sec respectively. After the storage period, the 
extrusion rates of the 25% and 50% samples dropped appreciably, with the larger decrease in the 
25% sample. The extrusion rate of the 75% sample did not undergo any drastic increase or 
decrease. A complete set of pre and post storage flexibility values was obtained only for the 25% 
surfactant vesicles, for which flexibility decreased by a factor of 87% after 42 days.  
4.2 Gel Permeation 
 We witnessed a clear diffusion of fluorescently tagged samples (0% surfactant liposomes, 
50% surfactant liposomes, and 100% surfactant micelles) through agarose gel at 10x 









Figure 10: Sample Diffusion Images  
 
Captured images of diffusion of 100% surfactant micelles on day 0 
The captured images were then quantitatively evaluated with ImageJ. We measured the 
intensity of fluorescence (represented by the “grayscale value” in our image analysis software) at 
various distances from the top of the image. Using these numbers, we were then able to calculate 
diffusivity values for each time point on each day that measurements were taken. In all samples 
we witnessed a constant decrease in diffusivity over the 600 second measurement period on all 
days. Shown below are the plots of diffusivity versus time for all three samples with data from 







Figure 11: Diffusivity Coefficients for Various Liposomes 
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Micelles Day 0 Micelles Day 1 Micelles Day 2 Micelles Day 7
 
 
The 0% liposomes showed no clear trend in diffusivity over the one-week storage period. 
As can be seen above, diffusivity values increased between day 0 and day 1, but then decreased 
between day 1 and day 7 to a value close to the initial diffusivity. Similarly, we observed no 
unidirectional trend for the surfactant micelles. Diffusivity decreased drastically between day 0 
and day 1, and showed a slight decrease between day 1 and day 2. However, by day 7 the 
diffusivity values were between those calculated for days 0 and 1. In contrast, the 50% surfactant 
sample showed a continuous increase in diffusivity between days 0 and 7.  
Comparatively, the 0% surfactant sample consistently had the lowest diffusivity values 
for all days of measurement. Initially, diffusivity was higher in the 100% surfactant micelles than 
the 50% liposomes. Over the course of the storage period, however, the micelles decreased in 
diffusivity while the 50% liposomes increased in diffusivity. Consequently, the 50% surfactant 
sample and 100% surfactant micelles had similar diffusivities at day 7. These data are 




Figure 12: Diffusivity Coefficient for Various Days Stored 
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0% Liposomes 50% Liposomes Surfactant Micelles
 
 
In all cases the diffusion coefficients eventually leveled off to a “final” value which we 
tabulated and performed some statistical calculations upon. As seen in the figures below, the 
different final diffusion coefficient values for each type of vesicle were distinct, with no overlap 
within one standard deviation of their averages. 
 











































In addition, we also examined the correlation between the final diffusion coefficient and 
the number of days the vesicles were stored. Based on the data points we collected, we found a 
strong correlation between increasing diffusion coefficients with increased storage time for the 
50% vesicles. There was a weaker negative correlation between storage time and days stored for 
0% vesicles. The pure micelles had little correlation between days stored and the resulting 
diffusion coefficient. Correlations are contrained by our limited data size. 
Figure 14: Final Diffusion Coefficients vs Days Stored 
 
Days Stored 0% 50% 100%
0 6.963E‐05 1.516E‐04 3.710E‐04
1 8.408E‐05 1.625E‐04 2.903E‐04
2 n/a 1.774E‐04 3.145E‐04
7 5.933E‐05 2.581E‐04 3.548E‐04









































4.2.1 Insulin Patch Modeling 
Using the parameters given in the methodology, a set of model delivery data was 
generated. As seen in the figures below, flux, delivery rate, and patch drug concentration 
decrease gradually over time as the amount of drug delivered reaches an asymptotic value. In 
general, increasing the surface area of contact of the patch and decreasing the barrier thickness 
tended to increase the curvature of the plots. Increasing the volume of the patch (while 
maintaining the same surface area) reduces the curvature of the graphs. Changing the initial 







































Delivery rates in gram units were converted to standard insulin units as defined by the 
World Health Organization. According to model parameters, the patch can deliver in a relatively 















1 0.068 1.496 1.496
2 0.061 1.344 2.840
3 0.056 1.228 4.067
4 0.051 1.122 5.190
5 0.047 1.025 6.215
6 0.043 0.937 7.152
7 0.039 0.856 8.009
8 0.036 0.783 8.791
9 0.033 0.715 9.507
































After testing our model with our initial configuration, we then tried more model 
parameters in order to change the delivery characteristics. The following three configurations 























1 0.145 3.186 3.186
2 0.116 2.554 5.740
3 0.095 2.085 7.824
4 0.077 1.702 9.527
5 0.063 1.390 10.916
6 0.052 1.135 12.051
7 0.042 0.926 12.977
8 0.034 0.756 13.733
9 0.028 0.617 14.350























































1 0.187 4.112 4.112
2 0.140 3.078 7.190
3 0.107 2.348 9.539
4 0.081 1.792 11.330
5 0.062 1.367 12.697
6 0.047 1.043 13.740
7 0.036 0.796 14.536
8 0.028 0.607 15.143
9 0.021 0.463 15.606
























































1 0.200 4.390 4.390
2 0.171 3.767 8.157
3 0.150 3.291 11.448
4 0.131 2.875 14.323
5 0.114 2.512 16.835
6 0.100 2.194 19.029
7 0.087 1.917 20.946
8 0.076 1.674 22.620
9 0.066 1.463 24.083



































As can be seen from figures 17, 18, and 19, changing the parameters allows us to achieve 
a number of delivery designs with drug delivery potentials ranging from 10 IIU to 25 IIU. With 
further tweaking, even more combinations are possible. Different combinations of surface area 






5.  Discussion 
Currently, needle injections are by far the most popular method of insulin delivery for 
diabetics. Although needles are an efficient and reliable means for administering drugs, needle-
based insulin therapies are often subject to low patient compliance, ultimately resulting in poor 
management of blood-glucose levels in diabetics (Cramer, 2004 and Morris et al., 1997). Issues 
such as needle anxiety, fear of pain associated with injections, and social embarrassment can all 
contribute to poor adherence to an insulin regimen (Korytkowski et al., 2005). Because the 
regular administration of insulin is crucial not only during acute hyperglycemic events but also 
for the long-term management of insulin-dependent diabetes, maintaining high patient 
compliance is a vital component of any successful insulin therapy.  
 The use of lipid vesicles, or liposomes, to deliver insulin across the skin is a potential 
alternative to traditional needle injections. Such vesicles have already been shown to transport 
insulin across intact mammalian skin, as well as to induce hypoglycemia in mice (Cevc et al., 
1998). More importantly, liposomes offer the advantage of being noninvasive. Therefore, an 
insulin-delivery regimen utilizing a vesicle delivery system could promote better compliance in 
insulin-dependent diabetics.  
A key determinant of whether a liposome can pass through the skin is vesicle size. Larger 
vesicles have greater difficulty passing through small pores on the surface of the skin, whereas 
smaller vesicles are much less inhibited. Thus any vesicle to be used as a drug carrier must 
remain stable in its small size after it is prepared. Flexibility is another important factor in vesicle 
penetration. Typically liposomal membranes consisting of a pure lipid bilayer are relatively rigid. 
The flexibility of liposomes may be enhanced by incorporation of surfactant in the lipid 




barrier (Cevc et al., 2002 and Van Kujik-Meuwissen et al., 1998). However, past studies have 
shown that surfactant-infused liposomes destabilize into other microscopic structures when kept 
in solution. Specifically, average vesicle radius is shown to vary inversely with surfactant 
concentration, and with increased surfactant levels, vesicles are shown to collapse into spherical 
and cylindrical micelles (Vinson et al., 1989 and Walter et al., 1991). 
5.1 DLS Size and Intensity Measurements 
Our data corroborates the inverse relationship between surfactant concentration and 
initial mean vesicle radius. In addition, consistent with our expectations, vesicles with more 
surfactant displayed greater variability in size over the course of two and six weeks. These 
fluctuations may represent the aggregation of liposomes into large vesicles which subsequently 
collapse into smaller particles, although further work is needed to identify the mechanisms 
underlying the observed trends. The marked decreases in the 50% and  75% surfactant samples 
in the six week trial suggest that these vesicles underwent a transition to the micelle state. This 
hypothesis is further supported by a change in the appearance of the fifty and seventy-five 
percent samples from cloudy to clear. Vinson et al. observed a similar change when their vesicles 
transitioned to the micelle phase (1989). Although the mean radius of both the 50 and 75% 
samples dropped to approximately 5 nm during the six week trial, the rapid decrease in vesicle 
size occurred much earlier in the 75% sample. It is therefore possible that the transition from 
vesicles to micelles occurs much sooner with higher levels of surfactant.  
DLS intensity, which is a measure of the number of light-scattering particles in solution, 
shows a limited relationship with mean radius. It was our initial belief that decreases in mean 
radius resulted solely from the disaggregation of large liposomes into smaller vesicles, and that 




have observed an increase in intensity (signifying an increase in the number of light-scattering 
particles) concomitant with each decrease in mean radius and vice versa. However, our data 
showed no such correspondence between the two trends, nor does the range of intensity 
fluctuation seem to correlate with the amount of surfactant in the vesicle sample. The 25% 
surfactant liposomes in the two week trial, for instance, showed a greater range of intensity 
values than the 50% sample. In the six week trials, the relatively low intensity values obtained 
for the 50% and 75% surfactant samples seem to correspond with the steep drop in mean radius, 
which can be explained by a sharp rise in the number of micelles in solution. Because surfactant 
micelles are too small to scatter light appreciably, light scattering and intensity would expectedly 
decrease as a result of their formation. Furthermore, the 25%, 50%, and 75% samples in the six 
week trials attained much lower values of intensity than the 0% surfactant liposomes. This is 
again indicative of the formation of surfactant micelles in the former three samples, whereas 
such micelles could not have formed in the surfactant-free 0% sample.  
Our data shows an association between mean particle radius and number of light-
scattering particles only when the trends suggest a transition from lipid vesicles to micelles. 
Essentially, mean radius decreases as surfactant molecules “fall off” the liposomes and form 
small micelle structures, which lowers the overall intensity of the sample. When this is not the 
case, however, mean radius and intensity trends show very little correlation, and the mechanisms 
underlying these intensity trends are not fully understood.  
5.2 Flexibility and Extrusion Rate 
 Flexibility, rather than size, is perhaps the most important determining factor in whether a 
lipid vesicle can carry drugs across the skin. In the case of rigid and flexible liposomes of equal 




irregular shapes. This is due to the ability of a flexible liposome to deform and “squeeze” 
through pores with radii smaller than the vesicle’s own.  
 As expected, our rigid 0% surfactant liposomes could not be extruded through pores 
smaller than the vesicles themselves. In contrast, all samples infused with surfactant showed 
some level of passage through the extruder. We believe that this demonstrates the ability of 
surfactant-infused liposomes to deform when passing through small openings, as described in 
previous studies. The 25% surfactant vesicles are the only sample for which we have valid 
flexibility data both before and after the six-week storage period, and our results show a marked 
decrease in flexibility over that time period. This may represent a “bleeding out” of surfactant 
molecules from the liposomes, leaving them more rigid as time progresses. When comparing the 
day 0 measurements for the 25% and 50% samples, we found the latter to have a greater 
flexibility index, corroborating the view that higher surfactant concentrations yield greater 
flexibility.  
 Extrusion rate, when compared to flexibility index, is a more direct gauge of a sample’s 
absolute capacity to traverse the extruder membranes. Both the 25% and 50% samples showed a 
smaller rate of extrusion after the storage period of six weeks, implying some loss of pore-
traversing capacity after storage. The 75% samples, however, showed very little change in 
extrusion rate after six weeks for reasons that are currently unclear, although we must note that 
these liposomes were stored for a shorter period of time than the 25% and 50% samples (26 days 
as opposed to 41 and 42 days, respectively).  
5.3 Gel Diffusion Experiment 
The continuous decrease in diffusivity values over our ten minute for each gel penetration 




diffusing through agarose, our values should have been constant if neither the vesicles nor gel 
changed during the data collection. The decrease in diffusivity during each measurement period 
was fitted to a power law. However, the power law regression for each trial was not a 
continuation of the regressions from previous days. The marked drop in diffusivity over the 
course of the ten minute trial can be attributed to factors associated with liposome diffusion 
through agarose gel and the measurements thereof; the power law regression does not describe 
the changes in diffusivity that result from storage of the vesicles. We offer several explanations 
for the inconstant diffusivities within each measurement period. First, structural changes in the 
vesicles and micelles induced by their passage through the agarose may have altered their 
diffusion properties. Second, structural changes in the agarose gel itself may have affected the 
passage of vesicles and micelles. Third, the concentration of fluorescent marker at any point on 
the slide may not have had a direct linear relationship with fluorescent intensity. Fourth, the 
fluorescent intensity of the visualized gel may have saturated to the point that changes in 
intensity could no longer be detected by our imaging system. Fifth, any dissociation of 
fluorophores from the vesicles and micelles as they passed through the gel would have decreased 
the apparent extent of diffusion, as the DiI markers we used fluoresce strongly only when 
embedded in a membrane. Due to the fact that the single-day diffusivity trends for all samples 
followed a power law, we believe that these drops in diffusivity resulted from a systematic 
phenomenon which we cannot definitively explain at this time.  
 For both the 0% surfactant liposomes and surfactant micelles, diffusivity trends did not 
change in one direction over the course of a week; diffusivity values for the 0% sample increased 
on the first two days and then decreased on the seventh day, while values for the micelles 




increased in diffusivity consistently between days 0 and 7. This contrasts with our extrusion rate 
data, in which extrusion rate decreased for the 50% sample. However, the 50% sample from the 
extrusion experiment was stored for a period of six weeks rather than one. During all 
measurement days, the 0% sample, consisting of rigid, surfactant-free liposomes, had the lowest 
diffusivity, most likely due to their inability to deform as they passed through the agarose. This 
supports our findings from the flexibility tests in which the 0% sample was the only one that 
could not pass through the extruder. This confirmed our hypothesis that rigid liposomes were the 
most ineffective at traversing both the polycarbonate membranes in the extruder as well as the 
agarose gel. 
 We initially suspected that the penetration efficacy of flexible liposomes was due to the 
formation of micelles in solution. Over time, surfactant molecules can become dislodged from 
lipid vesicle membranes, forming small, surfactant micelles and leaving more rigid, surfactant-
deprived vesicles. If this was the case, then the apparent passage of a flexible liposome solution 
through a barrier would actually represent the movement of micelles only. However, our data 
shows that the diffusivity of the 50% sample approaches that of the pure micelles at seven days. 
In addition, based on our DLS studies, the vesicle to micelle transition in our 50% sample does 
not occur until after a seven day period, suggesting that surfactant-infused vesicles in solution 
contributes to diffusion of the 50% sample. 
5.4 Insulin Patch Modeling 
Based on our findings, we can reason that while liposomes are a viable drug delivery 
vehicle, they must be stabilized in a medium that will not allow them to change in size over time. 
We have proposed that the best method of delivery is through a patch device that contains a 




heated or chemically activated to release the liposomes onto the skin. This matrix/patch device 
combines the stabilizing matrix that is necessary for the liposomes with the convenience of patch 
technology. We propose that the matrix be composed of a hydrogel, which has been 
demonstrated to both stabilize liposomes and release them onto an agarose skin-like barrier. A 
hydrogel is simply a network of synthetic polymers that can absorb a significant amount of 
water. Both hydrogels and liposomes can be stored for long periods of time as dry material, and 
reconstituted with the addition of water. We propose that a hydrogel/liposome mixture can also 
be submitted to the same treatment. However, little research has been performed on the viability 
of using hydrogels to stabilize liposomes. Recently, Mourtas et al. demonstrated that some 
liposome compositions such as propyleneglycol and transcutol CG are more amenable to 
stabilization by hydrogels, while the integrity of other liposome compositions are compromised 
upon integration with an aqueous gel. Four major factors control the diffusion characteristics of 
the model. They are diffusion coefficient, patch skin-contact surface area, volume, and initial 
concentration of drug in the patch. 
The diffusion coefficient describes the ability of the drug molecule to travel through the 
skin model and is a value that is difficult to change because it is inherent to the way the insulin 
molecule interacts with the skin barrier. A larger diffusion coefficient tends to produce steeper 
curves on graphs depicting drug concentration and delivery because drugs are delivered fast 
initially, exhausting the supply. A smaller diffusion coefficient tends to produce steadier, more 
linear delivery characteristics.  
In addition to the diffusion coefficient, the surface area of the patch in contact with the 
skin is also a huge factor in determining the delivery rates of the drug. Increased surface area 




would still remain the same, the increased lanes allow more traffic to pass through. Increasing 
surface area tends to increase the curvature of a delivery graph in a similar manner to the 
diffusion coefficient. Decreasing the surface area also tends to produce more stabilized, linear 
delivery at the cost of delivering less of the drug. 
Volume and initial concentration are related and are important in determining both the 
speed of drug delivery and the quantity of drug delivered. Because the rate of diffusion-
controlled delivery is ultimately determined by the concentration of the drug, the volume of a 
delivery system has a large effect on delivery rate. Increasing the volume (while keeping other 
factors the same) increases the potential amount of drug capable of being delivered by the patch 
and also reduces the curvature of the delivery profile. This is because a greater volume would 
decrease the concentration drop per unit time, and, as a result, would maintain more stable 
concentrations. Since delivery rate is directly related to concentrations, a higher, more stable 
concentration would result in higher, more linear delivery rates. The highway analogy would still 
work in this case; the volume would represent the size of the city that the traffic is originating 
from – all cities would produce the same initial traffic during rush hour (assuming every city has 
the same density of cars during the work week and the same size highways exiting the city) but 
larger cities will be able to sustain the flow of rush hour traffic much longer than a smaller city.  
Based on the results of the model and our assumptions, our theoretical patch could 
potentially be the only device needed to sustain the insulin needs of both type-1 and type-2 
diabetics. Instead of separating basal and bolus insulin doses using injections, diabetics could use 
our patch to obtain the initial bolus dose after meals (while patch delivery rates are high) and 
then continue to use our patch to sustain basal insulin needs (as the patch delivery rates decline). 




An online provider of diabetic information for medical practitioners, Family Practice 
Notebook, LLC, offers general dosing information per kilogram for diabetics. In general, these 
numbers range from 0.1 to 0.7 units of insulin per kilogram per day (Moses 2008). For a 75 
kilogram man, those numbers translate to 7.5 to 52.5 units a day; an amount which could feasibly 
be delivered by our model transdermal patch. By modifying the surface area and volume, a patch 























Our studies of liposome size, flexibility, and gel penetration have provided several key 
insights into the viability of liposomes for transdermal insulin delivery. In accordance with our 
initial hypothesis, size fluctuations were greater in samples of liposomes with a higher 
concentration of surfactant. Furthermore, after a period of two weeks, the mean radius of the 
50% sample underwent a drastic decrease, while the 75% sample experienced a similar decrease 
after only three days. These decreases were accompanied by a change in the appearance of our 
liposome solutions from cloudy to clear. All together, these data suggest an extensive transition 
of liposomes to surfactant micelles. We therefore conclude that our 50% and 75% flexible 
liposomes are not suited for storage periods of over two weeks and three days, respectively, as 
there are considerable structural changes that occur over the course of these time periods. In 
contrast, our 0% and 25% samples remained relatively stable over both two weeks and six 
weeks. A past study by Verma et al. (2003) found that the optimal vesicle size for drug delivery 
into skin is 60-70 nm, which was just above the mean radius for our 0% and 25% samples. 
Because the initial mean radius of our liposome samples can be adjusted based on the size of 
extrusion pores used in their preparation, we conclude that our 0% and 25% surfactant liposomes 
can be stored successfully from a size-stability standpoint.  
As expected, our data on vesicle flexibility suggests that surfactant-infused liposomes 
lose their flexible properties over time. In the case of our 25% sample, apparent flexibility 
decreased by over 80% over a period of six weeks. Data from this sample shows that vesicle 
flexibility can undergo drastic changes even if vesicle size remains relatively constant. Our 
flexibility data also indicate the effects of surfactant concentration on flexibility, as our 




the initial flexibility of the 50% surfactant sample was greater than that of the 25% sample. 
Because both vesicle size and flexibility are crucial factors for transdermal drug delivery, we 
conclude that of our four samples, the 25% and 50% vesicles are best suited for drug delivery 
after storage, although the storage period can be no longer than two weeks. In contrast, the 75% 
sample underwent a presumable vesicle to micelle transition after only three days, while our 0% 
sample was unable be extruded during the flexibility tests, indicating that it had the lowest pore-
traversing capacity. 
The diffusivity data of our liposome samples largely confirms the results seen in the 
flexibility experiment. The 0% surfactant liposomes, which were the most rigid, had the lowest 
diffusivity, while micelles (100% surfactant) had the highest diffusivity. Initially, the 50% 
surfactant liposomes had diffusivity values in between that of micelles and the 0% sample. 
Contrary to expectations, however, the diffusivity of the 50% sample increased and approached 
that of the micelles after seven days. Our data suggest that this rise in diffusivity of the 50% 
sample was not accomplished solely by the formation of new micelles since, during the size 
stability experiments, vesicles remained the dominant species in solution after one week. 
Although further work is needed to characterize the exact mechanism of the increase in 
diffusivity, our results show that at least some elements of our flexible liposomes are able to 
retain their ability to diffuse through a barrier after a week-long storage period.  
Our research confirmed our first two hypotheses, that liposomes with more surfactant 
exhibit more size fluctuation over storage, and that vesicle flexibility decreases during the 
storage period. Although our 0% surfactant liposomes showed the least variation in vesicle size, 
their limited flexibility and diffusivity make them unsuitable for transdermal drug delivery. 




diffuse through a barrier more effectively than their rigid counterparts. Furthermore, our 50% 
surfactant sample showed an increase in diffusivity over one week after formation, suggesting 
that these liposomes could potentially be an effective needleless insulin delivery agent within 
that timeframe. A patch delivery system could potentially be used to stabilize insulin-loaded 
flexible liposomes for an even longer period of time. Our model of a theoretical insulin patch 
shows that, according to our diffusivity data, such a system could deliver sufficient therapeutic 
amounts of insulin to adult diabetics.  
Limitations
 
Interpretation of our data is limited by several factors, some of which are listed below: 
 
1) Liposome and micelle concentrations were reported indirectly in terms of 
fluorescence, so all values are relative rather than absolute. In our interpretation of the data, 
many assumptions were made in correlating fluorescence intensity to concentration of liposome. 
2) The extent to which the fluorescent marker is being incorporated into the liposome is 
unknown. It is possible that the marker is not being incorporated at all, and the fluorescence we 
have visualized is simply of the marker traveling down the agarose gel. This is unlikely as DiI is 
known to fluoresce only when incorporated in a phospholipid membrane. 
3) It is not completely known that the formation of micelles is causing the increase in 
rigidity of the liposomes over time. We have only assumed this based on previously reported 
results by other groups. 
4) While we can use mathematical models to predict the feasibility of our liposomes in 
carrying insulin across the skin, testing these models by experimentation is imperative for future 




5) Many different materials for liposomes and surfactant exist, both in the literature and 
on the market. Our choice of egg PC and Tween 80 limits our ability to extrapolate our results to 
all liposome compositions. 
Future Work
In order to extend the significance of our work, we would like to perform a series of 
follow-up experiments. First, we would like to develop a method of quantifying the ratio of 
liposomes to micelles in any given mixture. To do this, we propose using size-exclusion 
chromatography, a common method used in chemistry to separate a heterogeneous mixture based 
on the size differences of the different species. Since micelles are much smaller than liposomes, 
they would have a different elution time on the column; we could determine the relative ratio of 
micelles to liposomes from the elution profile. In order to perform this experiment, we would 
have to label the liposomes with DiI before subjecting the mixture to the column. Once this assay 
is developed, we can use the data collected to confirm if formation of micelles is the cause of the 
decrease in liposome rigidity and size over time. 
 We would also like to perform a series of experiments that will directly link our results to 
transdermal insulin delivery using liposomes. We plan to repeat the gel permeation experiment 
with these insulin-encapsulated liposomes, visualize their penetration, and repeat the same 
measurements and calculations that we performed with the normal liposomes. It would be 
interesting to observe if there are any changes in diffusivity between the normal liposomes and 
the insulin-encapsulated liposomes. If these penetration experiments are deemed successful, we 
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Appendix A: Business Proposal 
Opportunity 
We believe that a patch technology developed to replace needle-based insulin delivery 
would be viable to develop and market due to the perceived need for an alternative to needles 
amongst the diabetic population. Specifically, we plan to target children and the elderly, two 
demographic groups who are the most needle-averse. Our insulin patch regimen would replace 
an insulin injection regimen for these populations. We will reach these groups through a push 
strategy aimed at endocrinologists and other medical professionals. Our main challenge will be 
persuading these professionals of the superiority of our product. However, because our core 
benefit proposition is improved patient compliance due to ease of use and effectiveness of the 
regimen, we do not foresee this being an issue. 
Team 
Our 10-person team possesses unique strengths that we believe will make our business 
successful. We are a close-knit group that has known and worked with each other successfully 
for almost four years. As a result, we know each others' strengths and weaknesses, we have 
established group norms and group dynamics, and we have honed our collective work ethic. 
Additionally, we have a wide range of skill sets -- members have backgrounds in chemical 
engineering, biology, business, and finance. Our team was created through the Gemstone 
Program at the University of Maryland, College Park. The Gemstone Program is a four-year, 
multidisciplinary research program that fosters leadership, teamwork, and the creation of original 
research. Students picked for this program are academically successful, passionate, and 






The estimated global prevalence of diabetes by age is: 0.22% of people 20 years old and 
younger, 9.6% of people between the ages of 21 and 59, and 20.9% of people 60 years and older. 
According to the American Diabetes Association (ADA), there are over 20.8 million children 
and adults in the United States who have diabetes, or approximately 7% of the population. There 
are also an estimated 40.1 million Americans with pre-diabetes conditions. Based on projections 
by the ADA, the total number of diagnosed diabetics could reach 29 million by 2050. Of these 
individuals, we expect 50-65% to require insulin. The 6 million people with Type I diabetes will 
need insulin administered to their bodies every day for the rest of their lives. Eventually, many 
patients with type II diabetes, especially as they age, will also require an insulin regimen. The 
blog DiabetesMonitor.com asserts that “The proportion of Non-Insulin-Dependent Diabetes 
Mellitus (NIDDM) patients treated with insulin increased with longer duration of diabetes, from 
22% at 0-4 years to 58% at more than 20 years.” These numbers indicate that the total projected 
number of diabetics who will use insulin is estimated to be 8.8 million in 2015, 10.5 million in 
2025, and close to 20 million by 2050. Those are growth rates of 19% and 90%, respectively – a 
huge increase. The rapid widening of the insulin market demands innovation of the system of 
administering insulin. 
Current Technology 
     Hypodermic needles, the current most popular method for insulin administration, have 
been used by diabetics for more than 90 years. Though widely used, they insufficiently meet our 
team's standards for glucose-control and patient compliance. Hypodermic needles are dangerous, 




adhere to their insulin treatment. Mintel reports that 40% of diabetics between the ages of 18-44 
and 25% of diabetics between the ages of 45-64 do not follow their insulin regimen closely. 
Insulin pumps are the second most widely used method of insulin administration. While 
the pump removes the discomfort of needles, it is unwieldy and must be secured to the body via 
a catheter. 
Our vision is a technology that regulates blood-glucose levels steadily, as an insulin 
pump would, but does not compromise the integrity of the dermis to environmental factors. 
Additionally, our technology must support high levels of patient compliance in that it is easy to 
use and easy to remember to use. 
Our Product 
Thus far, our team has completed preliminary research exploring the viability of using 
deformable liposome vesicles to transport insulin through the dermis and into the bloodstream. 
Results have been promising. We hope to use vesicles loaded with insulin to form easy dose 
patches ranging from slow-release for use all day, to fast-acting, for use after meals. Each patch 
would contain a set amount of the drug, so overdosing would not be a factor. The patch would be 
left on for a minimum of a set amount of time, after which it could be removed. Patches would 
be color-coded by dose type, and a monitor included with the system would keep track of time 
and blood-sugar levels. We hope to develop a gel-matrix delivery system that would be activated 
by body heat, for use with the insulin-loaded vesicles. This delivery system is what we hope to 
patent. Hurdles to securing intellectual property rights include developing the system, applying 







Other companies pursuing non-invasive insulin administration include Phosphagenics 
Limited, located in Melbourne, Australia, and Encapsulation Systems, Inc, located in 
Pennsylvania. Phosphagenics has developed a proprietary gel that works with the skin's natural 
mechanisms to foster drug absorption, while Encapsulation Systems Inc, has developed an 
ultrasonic patch that dilates pores, allowing insulin molecules to penetrate the dermis and enter 
the blood stream. Both of these systems are currently undergoing phase 2 clinical trials. While 
they are similar to our proposed technology in that they are non-invasive, we feel that our patch 
has a competitive edge. Topical gels may get brushed or washed off or not rubbed in adequately, 
and the ultrasonic patch must be used with an insulin-pump like system, kept on the body at all 
times. The clean and compact aspects of our proposed patch technology give it an advantage 
over these technologies. 
Future Works 
Our team is currently entering the initial stages of development. We have proven the 
viability of our liposome formulation to cross a skin-like membrane (agar gel). Now, we need to 
test the viability of the liposomes loaded with insulin through a more realistic membrane such as 
pig skin or human cadaver skin. This should take about five months. Over the five months after 
that, we will formulate a gel matrix to stabilize the liposomes. Ten months from now, we should 
be able to proceed to developing a complete prototype for the patch. 
Following the development of our prototype, we will seek FDA approval to begin clinical 
trials. Extensive data collection will be necessary to pass FDA approval, therefore we will need 
to secure superior materials, equipment and lab space. Our current funding needs are $28,000 




$5,000 - Purchase new extruder 
$700 - Materials for liposome formation 
$700 - Insulin 
$1,200 - Pig skin and human cadaver skin 
$2,000 per month for 10 months - Rental of lab space with access to appropriate equipment 





Appendix B: Future Research Proposal  
Proposal: Elastic Nano-Vesicles for Transdermal Delivery  
 
Statement of Need 
 
What is the Need? 
Today, if you find out that you were diabetic, you better hope that you were not afraid of 
needles. Today, if you have to take your young child to the doctor’s for a vaccination, you better 
be prepared to fight through the thrashing, crying, screaming, puffy eyes, and tear-induced stuffy 
noses as you watch nervously as the nurse walks into the room with that sharp needle. Today, in 
the places less fortunate than the United States, millions of diabetics and millions of children are 
dying because they don’t have the luxury of the medical attention required to treat diabetes or to 
receive vaccinations. 
 Fortunately, scientists and engineers are working hard to produce novel nano-scale drug 
delivery methods that will simplify the diabetics life, put to ease the frantic mother and her 
screaming child, and give a chance to the possibly billions of people who need medical treatment 
that today is too complex to adequately serve them. Three companies have announced novel drug 
carriers that can transport life-saving molecules across undamaged skin, and they have received a 
considerable amount of attention for the potential impact their technology could have. 
Shockingly, not one of these companies operates in the United States. 
 Need is causation in many different forms: a man dying of thirst needs water, a former 
champion needs redemption, a less fortunate human being needs aid from a more fortunate one. 
The need for the development of these novel drug carriers in the United States is the need of the 




the internet, to help out both her own people and her less fortunate neighbors and to regain the 
edge in a field that she should, for any reason, not be number one. 
 
What’s Wrong with the Technology Today? 
The impermeability of the skins provides the greatest challenge in developing 
transdermal delivery technology. Traditionally, it is stated that drugs over 500 Daltons cannot 
cross the skin barrier unassisted (1). In navigating the barrier function of the skin, the stratum 
corneum (SC) is the primary obstacle. This layer of the skin is on average 20 cells thick and 
consists of overlapping layers of terminally-differentiated corneocytes bound by extra-cellular 
lipids. The composite of these materials creates a “brick-and-mortar” feel to the SC, which 
creates difficult boundary to penetrate for the majority of molecules (2). Currently only small, 
hydrophobic molecules are able to diffuse through the lipid layers of the SC and be delivered 
into the body (3).  
Despite their successes, the three drug carriers mentioned before – Transfersomes®, 
Ethosomes, and TPM-02, are still not relatively well understood. These novel drug carriers have 
been studied enough to show that they are effective in delivering certain category of drugs. 
Transfersomes® are being tested for topical analgesics (4); Ethosomes® have been shown to 
deliver the hormone testosterone better than previous technologies (5); TPM-02 is finished with 
phase I trials as a method of delivering insulin to type 1 diabetics (Phosphagenics press release). 
These products are being developed in spite of the fact that a true understanding of the 
mechanism of function is not well understood. While this in itself is not an issue, it is important 
to have a true understanding of the mechanism of function in order to fully realize the potential 
of transdermal delivery. The first generation of products, with perhaps the exception of TPM-02 




transdermal methods rather than breaking ground on previously undeliverable drugs (4). While 
their research has shown that delivery of these drugs is possible, inconsistency in the 
reproducibility of the results often hinder progress.  
 
What Do We Want to Do? 
Of interest to us is a report from Cevc et al. which reported a novel highly deformable 
liposome formulation (called Transfersomes®) are capable of permeating undamaged skin intact 
and deliver drug agents like insulin at therapeutically significant levels (6). Unlike the transport 
of drugs through a chemical activity gradient (concentration), Cevc states that ultra-deformable 
Transfersomes® penetrate the skin due to vesicle hydration across the water gradient across the 
stratum corneum, and the rate of penetration is dependent on the rigidity of the penetrating 
liposome. Cevc further claims that the rate of delivery is independent of the liposome 
concentration (7). 
Although Cevc has reported outstanding results for Transfersomes® in delivering 
therapeutic levels of large drug molecules such as insulin, his results were repeated with mixed 
levels of success (6, 8). El Maghraby et al. reported only one to three percent of drug applied 
topically was delivered in 30 minutes compared to the near 50% statistic reported by Cevc. Later 
on, three separate in vivo studies involving tape-stripping of human skin reported that surfactant 
vesicles showed deep penetration into the stratum corneum within an hour (9). 
 We do not doubt the effectiveness of Cevc’s Transfersome® formulation nor we deny 
that vesicle elasticity and the hydration gradient has an impact on delivery. We have also 
noticed, however, that Ethosomes and TPM-02 also deliver based on claims of elasticity despite 
the three all having claims to separate intellectual property. From our review of literature and 




at play (at least partially different) and we will examine the various elements of these elastic 
vesicle systems to discover components of the true mechanism of function, one that we believe 
can tie together all three of the novel drug carries we have mentioned. With a better 
understanding of the mechanism, we believe we can build a more robust product capable of 
delivering a greater variety of drugs with greater efficiency. 
 Due to our unique location at the University of Maryland, we can potentially take 
advantage of the hundreds of peptide drugs in development, some of which may hold the cure to 
cancers, HIV vaccination, and some of the other biggest challenges in medical treatment today. 
Even with a technology of equal effectiveness, our unique proximity to the heart of 
biotechnology research will allow us to compete successfully against foreign technologies. 
 Regardless of future product and intellectual property possibilities, our research will at 
least contribute to the fundamental understanding of these novel vesicle systems. While potential 
future market shares and revenue streams are uncertain, what is certain is that any contribution 
we make to a breakthrough transdermal technology will undoubtedly affect everyone whose lives 




When attempting to make improvements to a piece of technology, whether it’s upgrading 
a computer, modifying a car, updating computer code, or redefining vesicle transdermal delivery 
mechanisms, the first priority be to have a solid general understanding of how the entire system 




rest of the system serves as a critical prerequisite for any attempts to modify the system for a 
certain benefit. 
As such, we will partition our research into two major phases to reflect the steps 
necessary to accomplish our goal of making improvements to Transfersome® and other elastic 
vesicle technology. The first phase will consist of experiments associated with familiarization 
and tabulation of different vesicle properties and their effect on transdermal delivery.  We will 
identify the variables with the greatest impact on the vesicle system performance and document 
how variations in these variables cause changes in penetration characteristics of skin or skin-like 
barriers.  
Once we understand the components of the elastic vesicle system and their relative 
impact on the ultimate goal of efficient delivery, we enter the second phase of our research. 
During this phase, we will take an analytical approach in hypothesizing and verifying the driving 
forces behind the relationships we discovered in the first phase. Instead of just figuring out what 
happens, we will focus on why it happens and how each phenomenon pieces together to 
formulate a cohesive mechanism for drug delivery at the skin. 
The benefit of taking a systematic, step-by-step approach is that we can easily backtrack 
to familiar territory and re-adjust in the likely case that our research produces an unexpected 
result. In addition, through our systematic approach each negative result will provide as much 
information as positive results in directing future research. 
Previous Work 
 Over the past two years, we have performed preliminary experiments to investigate the 
effect of different lipid compositions on the stability and flexibility of the liposome over a six-




lipid compositions (i.e., to study their rate of diffusion across a skin-like model membrane.  
Although this was only a preliminary investigation, we were able to conclude that lipid 
composition greatly affects the stability in size and flexibility of the liposome during long term 
storage.  Our membrane permeation studies showed that while liposomes with greater surfactant 
concentration seemed to diffuse through the skin at a higher rate, they were also the least stable 
in terms of size, and are therefore not viable for manufacture.   We were unable to make concrete 
justifications for our observations, and there were little or no comprehensive studies 
characterization of liposomes in the literature.  Our experience with liposome research has led us 
to propose this systematic approach to liposome characterization, which would aid not only our 
own research, but all liposome research aimed at drug delivery.  .    
Specific Aims: 
Milestone I:  
Familiarization with Elastic Vesicles and Tabulation of Cause and Effect Relationships 
 We expect to spend about nine months in phase one of our research. We justify spending 
a significant amount of time familiarizing and exploring our vesicle system by drawing an 
analogy to driving around Washington D.C. for the first time. Ten minutes of simple preparation 
before heading out the driveway could potentially save hours of time circling unfamiliar streets. 
There is a small chance that our research will miraculously turn out the exact results we want, 
but the far greater, almost infinitely greater, possibility is that something unexpected will happen. 
In these cases, we will be prepared and first phase of our research will be both the map to guide 
us back to familiar territory and the framework to make connections we otherwise would not 




 In general, we are looking to replicate the spectrum of results (as opposed to the best 
result) published in literature and to isolate trends associated with modifying certain variables. In 
addition, we want to visualize as many of the processes and phenomena we encounter as 
possible.  
The ultimate goal of all these efforts is to evaluate the components of the current 
mechanism and label each part as incorrect, incomplete, or correct. We hope to have charts 
tabulating the performance of the spectrum of possible variable combinations. From these, we 
can analyze and visualize trends in a systematic fashion. We hope to be able to draw information 
from these trends for phase two of our research. 
In particular, there are several quantitative and qualitative measurements that we are 
interested in: 
• Vesicle Size: Vesicle size fluctuations and equilibrium will be tabulated for each 
composition of vesicle using dynamic light scattering (DLS). Vesicle size, especially at 
equilibrium, is interesting because it provides information on the natural stability of that 
formulation. Vesicle size fluctuations may be indicative of structural changes in the 
vesicle that may be an important part of the delivery mechanism 
• Vesicle Rigidity: Vesicle rigidity will be tabulated for all vesicle compositions. These 
measurements will be made by extrusion (using a pressure-driven extruder) through pore 
sizes smaller than the vesicle itself. Rigidity is related to the proportion of the pore size 
and the diameter of the vesicle. Vesicle rigidity is stated as one of the two biggest factors 
in the delivery of Transfersomes® across the skin barrier according to Cevc (7). 
• Vesicle Penetration through Skin or Skin Model: The penetration of vesicles into and 




fluorescent lipid dyes. DiI is incorporated into the lipid structure of the liposome and will 
fluoresce noticeably less when not incorporated into a liposome. Skin will be prepared for 
microscopy by sectioning into thin slices. 
• Occlusive Vs Non-occlusive Delivery: The importance of preventing moisture loss will be 
monitored for the delivery of all vesicle compositions. Occlusive delivery prevents water 
loss from the delivery medium. A custom diffusion cell, described by Cevc et al., where 
one end is in contact with an aqueous solution and the other side open to a controlled 
humidity environment, will be used to control the moisture loss of the delivery medium 
(7). Delivery of Transferomes® consisting of sodium cholate is dependent on non-
occlusion during delivery in order to penetrate the skin barrier. We want to see if all 
vesicle compositions require the same condition. 
• Effect of Vesicle Ethanol Composition on Delivery: Vesicles with varying amounts of 
ethanol in their structure will be delivered non-occlusively through porcine skin in the 
custom diffusion cell mentioned above. Particularly with Transfersomes®, the effect of 
the composition of ethanol in the vesicle on delivery is not very well understood. Ethanol 
is a shared component in the three major drug carriers discussed in the statement of need.  
• Effect of Pre-treatment on Lipid Structure of Skin: We will measure the difference in 
transport of fluorescently-tagged vesicles through porcine skin pre-treated with 
surfactant, ethanol, and surfactant-ethanol combinations. We will use the custom 
diffusion cell described above. We will also take electron microscopy images of the 
porcine skin surface before and after pre-treatment in order to visualize the interaction of 
surfactant, ethanol, and combination of the two on skin lipids. While we do not believe 




interactions on the surface of the skin will reflect interaction that happen while vesicles 
are traveling through lipid channels in the skin. 
Milestone II:  
Formation and Validation of New Hypotheses on Elastic Vesicle Delivery Mechanism 
If the journey to the first milestone were a collection of traffic reports on which route is 
the best way to travel, then the second phase of our journey would be analogous to investigations 
on why certain routes are better than others. Vesicle formulations would be the equivalent of 
traffic routes and we are attempting to figure out why certain routes provide better results than 
others. Is it because of the vesicle equivalents of traffic lights? Tolls? H-O-V Lanes? With this 
information in hand we can design a new traffic pattern, or vesicle, using the best of what was 
before and adding new features that fixes problems with the previous version. 
In general, we are looking for signs of vesicle deterioration during transport through skin 
and the modification of lipid channels by earlier vesicles to prevent deterioration of later vesicles 
as they traverse. Most of our experiments will attempt to provide indirect evidence through 
testing in analogous in vitro settings. 
The structure of experimentation in this phase will consist of hypothesis testing based on 
trends seen in the first phase. For example, if we noticed in the first phase that there was an 
optimum 15% ethanol concentration for Transfersome® delivery and we noticed from our 
electron microscopy images that ethanol/surfactant pre-treatments caused integration of 
surfactants into the lipid structure, we would hypothesize that vesicles change the structure of the 
surrounding lipid channel by “bleeding” surfactant and integrating them into the channel, 
somehow facilitating drug delivery as a result. From this hypothesis, we then follow the 




trends to formulate a new hypothesis and failure to reject our hypothesis will result in the next 
logical progression in testing the hypothesis. With this method, we can always take a step or two 
back at potential dead-ends to re-evaluate and adjust. 
One of our major challenges in the second is to ensure that our detection methods are 
accurate. It is almost impossible to detect vesicles directly, and they are usually measured 
through an indirect method such as fluorescent markers and dynamic light scattering. In phase I, 
we used methods previously published to be accurate. Because we are attempting to detect signs 
of novel mechanisms that may not have necessarily been explored before, we will spend 
significant efforts to cross-check and thoroughly understand our detection methods before we 
rely on them. In many cases we expect the usual detection methods to be sufficient, but because 
they are being used in a new situation we still have to be careful. 
In phase II, we will be exploring these general concepts in order to extract a mechanism 
from our data: 
• Vesicles Compositional Changes: Using equipment like extruders, DLS and other 
analytical tools ( ex. Differential scanning calorimetry), we want to study the changes in 
vesicle composition after being stressed through small pores through indirect 
measurements like flexibility, size distribution, and membrane phase behavior. We will 
deliver these “stressed” vesicles through porcine skin and compare them with the 
performance of fresh vesicles. These measurements will provide some indirect evidence 
to potential changes in the vesicle as it traverses the pores of the skin. Continued rounds 
of extrusion can reveal if these vesicles will “expire” after a certain number of stresses. 




• Vesicle Interactions with polar/non-polar interfaces: We will use extrusion, DLS, and 
other analytic tools to examine characteristics of aqueous vesicles before and after 
interaction with lipids and other non-polar materials in liquid and gel forms. While 
information is known about vesicles stability in polar and non-polar solvents, we want to 
how vesicles originally stable in the aqueous phase behave when exposed to non-polar 
environments like lipid channels in the skin, particularly in the presence of lipid-
solubilizing ethanol. We believe some vesicle degradation is inevitable when exposed to 
the lipid environment but we also believe that the destabilizing of vesicles initially in the 
channel provides stability to future vesicles in that channel. These experiments will 
address the deterioration aspect of our mechanism. 
• Lipid Channel Modification: We will use the custom diffusion cell described in phase I to 
transport Transfersomes® through a hydrophobic gel. Then, we will see if the gel 
permeation to polar compounds like water has changed. We will use standard fluorescent 
marker techniques to detect water transport. These series of experiments will address 
both the deterioration and the transport-facilitating effect of previous vesicles on the 
transport of future vesicles portion of our mechanism. 
• Surfactant Channel Facilitation of Transport: Using the custom diffusion cell described 
above, we will see if transporting Transfersomes® through a hydrophobic gel 
incorporated with surfactant improves the transport rate. We will use DiI incorporated 
into the vesicle structure to track vesicle progress. These experiments will address the 





Potential Impact of Proposed Research on the Development of Liposome Drug Delivery 
Nanotechnology and Future Prospects 
Once a mechanism for transdermal liposome delivery of peptides is confirmed, it will be possible 
to use this information in designing a product for drug delivery.  For example, our previous 
research has confirmed that the flexible liposomes required for delivery of large macromolecules 
is also quite unstable when stored for long periods of time.  Thus, in order for these vesicles to be 
manufactured into a viable product, the liposomes must somehow be stabilized in a gel-like 
media.  New information we learn in the 24 months of experimenting with the effect vesicle 
properties on delivery characteristics will allow us to formulate similar designs.   
 
References 
1. M. Foldarvi, PSTT 3, 417 (2000). 
2. G. K. Menon, Advanced drug delivery reviews 54, S3 (2002). 
3. B. W. Barry, DDT 6, 967 (2001). 
4. G. Cevc, U. Vierl, S. Mazgareanu, International Journal of Pharmaceutics 360, 18 
(2008). 
5. M. J. Choi, H. I. Maibach, International Journal of Cosmetic Science 27, 211 (2005). 
6. D. G. Gregor Cevc, Juliane Stieber, Andraes Schatzlein, Gabriele Blume, Biochimica et 
Biophysica Acta 1368, 201 (1998). 
7. G. Cevc, D. Gebauer, Biophysical Journal 84, 1010 (2003). 
8. G. Cevc, Clincial Pharmacokinetics 42, 461 (2003). 
9. P. L. Honeywell-Nguyen, H. W. W. Groenink, J. A. Bouwstra, Journal of Liposome 
Research 16, 273 (2006). 
 
 
 101 
 
